OA19248A - Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof. - Google Patents
Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof. Download PDFInfo
- Publication number
- OA19248A OA19248A OA1201900250 OA19248A OA 19248 A OA19248 A OA 19248A OA 1201900250 OA1201900250 OA 1201900250 OA 19248 A OA19248 A OA 19248A
- Authority
- OA
- OAPI
- Prior art keywords
- cells
- formulation
- buffer
- virus
- antibody
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 175
- 238000009472 formulation Methods 0.000 title claims abstract description 125
- 102000004965 antibodies Human genes 0.000 title claims abstract description 98
- 108090001123 antibodies Proteins 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 59
- 238000004113 cell culture Methods 0.000 title claims abstract description 29
- 230000002776 aggregation Effects 0.000 title claims abstract description 22
- 238000004220 aggregation Methods 0.000 title claims abstract description 22
- 210000004962 mammalian cells Anatomy 0.000 title claims description 6
- 230000002708 enhancing Effects 0.000 title description 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims abstract description 45
- 102000005614 monoclonal antibodies Human genes 0.000 claims abstract description 45
- 238000000746 purification Methods 0.000 claims abstract description 33
- 239000000178 monomer Substances 0.000 claims abstract description 18
- 238000011084 recovery Methods 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 241000725619 Dengue virus Species 0.000 claims abstract description 11
- 241000711798 Rabies lyssavirus Species 0.000 claims abstract description 6
- 210000004027 cells Anatomy 0.000 claims description 120
- 102000004169 proteins and genes Human genes 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 101
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 81
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 73
- 229940068968 Polysorbate 80 Drugs 0.000 claims description 71
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 71
- 229920000053 polysorbate 80 Polymers 0.000 claims description 71
- -1 sulfoethyl Chemical group 0.000 claims description 56
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 54
- 208000001490 Dengue Diseases 0.000 claims description 53
- 206010012310 Dengue fever Diseases 0.000 claims description 53
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 51
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 48
- 239000005720 sucrose Substances 0.000 claims description 48
- 230000001225 therapeutic Effects 0.000 claims description 48
- 239000004475 Arginine Substances 0.000 claims description 47
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 45
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 102000025417 antigen binding proteins Human genes 0.000 claims description 38
- 108091000829 antigen binding proteins Proteins 0.000 claims description 38
- 238000004587 chromatography analysis Methods 0.000 claims description 37
- 230000003612 virological Effects 0.000 claims description 33
- 239000007979 citrate buffer Substances 0.000 claims description 32
- 239000012527 feed solution Substances 0.000 claims description 32
- 239000002609 media Substances 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 30
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 29
- 241000282414 Homo sapiens Species 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 22
- 238000004140 cleaning Methods 0.000 claims description 22
- 238000001042 affinity chromatography Methods 0.000 claims description 21
- 239000011347 resin Substances 0.000 claims description 20
- 229920005989 resin Polymers 0.000 claims description 20
- 238000005277 cation exchange chromatography Methods 0.000 claims description 19
- 206010037742 Rabies Diseases 0.000 claims description 18
- 239000006172 buffering agent Substances 0.000 claims description 18
- 238000011067 equilibration Methods 0.000 claims description 18
- 239000008363 phosphate buffer Substances 0.000 claims description 18
- 238000005571 anion exchange chromatography Methods 0.000 claims description 17
- 229920002684 Sepharose Polymers 0.000 claims description 16
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- 239000003381 stabilizer Substances 0.000 claims description 16
- 239000006143 cell culture media Substances 0.000 claims description 15
- 239000006167 equilibration buffer Substances 0.000 claims description 15
- 239000012541 Fractogel® Substances 0.000 claims description 14
- 150000001768 cations Chemical class 0.000 claims description 14
- 238000011068 load Methods 0.000 claims description 14
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 14
- 239000000919 ceramic Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000012539 chromatography resin Substances 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 238000009295 crossflow filtration Methods 0.000 claims description 11
- 230000002779 inactivation Effects 0.000 claims description 11
- 238000003860 storage Methods 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 239000007640 basal medium Substances 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 238000003306 harvesting Methods 0.000 claims description 10
- 210000003292 kidney cell Anatomy 0.000 claims description 10
- 239000012515 MabSelect SuRe Substances 0.000 claims description 9
- 230000010261 cell growth Effects 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000001728 nano-filtration Methods 0.000 claims description 9
- 239000011534 wash buffer Substances 0.000 claims description 9
- 206010053317 Hydrophobia Diseases 0.000 claims description 8
- 210000003734 Kidney Anatomy 0.000 claims description 8
- 239000012536 storage buffer Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 239000012149 elution buffer Substances 0.000 claims description 7
- 230000001965 increased Effects 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 102000037197 Anion exchangers Human genes 0.000 claims description 6
- 108091006437 Anion exchangers Proteins 0.000 claims description 6
- 229920001429 Chelating resin Polymers 0.000 claims description 6
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims description 6
- 102100011932 HSD17B10 Human genes 0.000 claims description 6
- 101710036502 HSD17B10 Proteins 0.000 claims description 6
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 claims description 6
- 241001596784 Pegasus Species 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 claims description 6
- 108010010371 efalizumab Proteins 0.000 claims description 6
- 229960000284 efalizumab Drugs 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 125000005645 linoleyl group Chemical group 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000006011 modification reaction Methods 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 6
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 210000002683 Foot Anatomy 0.000 claims description 5
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 5
- 210000004072 Lung Anatomy 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 108091006028 chimera Proteins 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229920002496 poly(ether sulfone) Polymers 0.000 claims description 5
- 229920003208 poly(ethylene sulfide) Polymers 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 108010005144 Bevacizumab Proteins 0.000 claims description 4
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 108010022830 Cetuximab Proteins 0.000 claims description 4
- 241000282552 Chlorocebus aethiops Species 0.000 claims description 4
- 230000037250 Clearance Effects 0.000 claims description 4
- 241000699800 Cricetinae Species 0.000 claims description 4
- 108010084740 Daclizumab Proteins 0.000 claims description 4
- 241001115402 Ebolavirus Species 0.000 claims description 4
- 108010091266 Gemtuzumab Proteins 0.000 claims description 4
- 210000004408 Hybridomas Anatomy 0.000 claims description 4
- 108010053490 Infliximab Proteins 0.000 claims description 4
- 108090000393 Muromonab-CD3 Proteins 0.000 claims description 4
- 229960003816 Muromonab-CD3 Drugs 0.000 claims description 4
- 108010029597 Omalizumab Proteins 0.000 claims description 4
- 229960000470 Omalizumab Drugs 0.000 claims description 4
- 108010010691 Trastuzumab Proteins 0.000 claims description 4
- 240000004652 Vaccinium ovalifolium Species 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 150000001720 carbohydrates Chemical group 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 229960005395 cetuximab Drugs 0.000 claims description 4
- 230000035512 clearance Effects 0.000 claims description 4
- 229960002806 daclizumab Drugs 0.000 claims description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 238000011026 diafiltration Methods 0.000 claims description 4
- 108010063231 eculizumab Proteins 0.000 claims description 4
- 229960002224 eculizumab Drugs 0.000 claims description 4
- 229960000578 gemtuzumab Drugs 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 4
- 229960000598 infliximab Drugs 0.000 claims description 4
- 238000011140 membrane chromatography Methods 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 4
- 229960005267 tositumomab Drugs 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- YRULUXDRMGWMDA-UHFFFAOYSA-K 2-(2-ethylhexanoyloxy)ethanethiolate;methyltin(3+) Chemical compound CCCCC(CC)C(=O)OCCS[Sn](C)(SCCOC(=O)C(CC)CCCC)SCCOC(=O)C(CC)CCCC YRULUXDRMGWMDA-UHFFFAOYSA-K 0.000 claims description 3
- KKMIHKCGXQMFEU-UHFFFAOYSA-N 2-[dimethyl(tetradecyl)azaniumyl]acetate Chemical group CCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O KKMIHKCGXQMFEU-UHFFFAOYSA-N 0.000 claims description 3
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 claims description 3
- SNQVCAOGQHOSEN-UHFFFAOYSA-N 2-[methyl(octadecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)=O SNQVCAOGQHOSEN-UHFFFAOYSA-N 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- DIROHOMJLWMERM-UHFFFAOYSA-N 3-[dimethyl(octadecyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O DIROHOMJLWMERM-UHFFFAOYSA-N 0.000 claims description 3
- 108090000206 Autoantibodies Proteins 0.000 claims description 3
- 102000003852 Autoantibodies Human genes 0.000 claims description 3
- 241000699802 Cricetulus griseus Species 0.000 claims description 3
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 3
- 239000004713 Cyclic olefin copolymer Substances 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 230000035693 Fab Effects 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229960000367 Inositol Drugs 0.000 claims description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims description 3
- NZXVYLJKFYSEPO-UHFFFAOYSA-N N-[3-(dimethylamino)propyl]-16-methylheptadecanamide Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCCN(C)C NZXVYLJKFYSEPO-UHFFFAOYSA-N 0.000 claims description 3
- 210000001672 Ovary Anatomy 0.000 claims description 3
- 229940044519 Poloxamer 188 Drugs 0.000 claims description 3
- 229940068977 Polysorbate 20 Drugs 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229940068965 Polysorbates Drugs 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K Potassium citrate Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 3
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 3
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 229960003487 Xylose Drugs 0.000 claims description 3
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims description 3
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- 229960002635 potassium citrate Drugs 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 230000002207 retinal Effects 0.000 claims description 3
- 235000020945 retinal Nutrition 0.000 claims description 3
- 239000011604 retinal Substances 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 125000000185 sucrose group Chemical group 0.000 claims description 3
- 239000011791 tripotassium citrate Substances 0.000 claims description 3
- 235000015870 tripotassium citrate Nutrition 0.000 claims description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 claims description 3
- 239000011778 trisodium citrate Substances 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- ZNAMMSOYKPMPGC-HTOAHKCRSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(2-phenylethylsulfanyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1SCCC1=CC=CC=C1 ZNAMMSOYKPMPGC-HTOAHKCRSA-N 0.000 claims description 2
- PMOOKBAYUNEHOF-IKHMJLPLSA-N (2S,3S,4S,5R,6R)-6-[[(4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(1R,2R,3S,4R)-2,3,4-trihydroxycyclohexyl]oxyoxane-2-carboxylic acid Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)OC1CC[C@]2(C)[C@H]3CCC=4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(CC1=4)(C)C)C(O)=O)C(O)=O)[C@@H]1CC[C@@H](O)[C@H](O)[C@H]1O PMOOKBAYUNEHOF-IKHMJLPLSA-N 0.000 claims description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N AC1LDCW0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims description 2
- 101700039884 AGE1 Proteins 0.000 claims description 2
- 229950005186 Abagovomab Drugs 0.000 claims description 2
- 108010007562 Adalimumab Proteins 0.000 claims description 2
- 108010090726 Alefacept Proteins 0.000 claims description 2
- 108010090838 Alemtuzumab Proteins 0.000 claims description 2
- 241000710929 Alphavirus Species 0.000 claims description 2
- 229950005725 Arcitumomab Drugs 0.000 claims description 2
- 229940090047 Auto-Injector Drugs 0.000 claims description 2
- 108010067213 Basiliximab Proteins 0.000 claims description 2
- 229950007843 Bavituximab Drugs 0.000 claims description 2
- 229950003269 Bectumomab Drugs 0.000 claims description 2
- 229950002903 Bivatuzumab Drugs 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 108010034751 CDP 571 Proteins 0.000 claims description 2
- 101700051744 CLE-1 Proteins 0.000 claims description 2
- 101700074214 CM32 Proteins 0.000 claims description 2
- 101700066277 COS-1 Proteins 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims description 2
- 241000347972 Caucasus prunus virus Species 0.000 claims description 2
- 241001502567 Chikungunya virus Species 0.000 claims description 2
- 229950002334 Clenoliximab Drugs 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 108010043242 Denosumab Proteins 0.000 claims description 2
- 108010070635 Edrecolomab Proteins 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 229950009760 Epratuzumab Drugs 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 229950009569 Etaracizumab Drugs 0.000 claims description 2
- 108010042984 FG 3019 Proteins 0.000 claims description 2
- 239000012605 Fractogel® EMD TMAE Substances 0.000 claims description 2
- 229950001109 Galiximab Drugs 0.000 claims description 2
- 101710027122 H2B.10 Proteins 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 108010024848 IMC-3G3 Proteins 0.000 claims description 2
- 102000012745 Immunoglobulin Subunits Human genes 0.000 claims description 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 claims description 2
- 108010089187 Ipilimumab Proteins 0.000 claims description 2
- 101700077860 KCNH4 Proteins 0.000 claims description 2
- 102100006987 KCNH4 Human genes 0.000 claims description 2
- 229950000518 Labetuzumab Drugs 0.000 claims description 2
- CHFSOFHQIZKQCR-UHFFFAOYSA-N Licostinel Chemical compound N1C(=O)C(=O)NC2=C1C=C(Cl)C(Cl)=C2[N+](=O)[O-] CHFSOFHQIZKQCR-UHFFFAOYSA-N 0.000 claims description 2
- 229950002950 Lintuzumab Drugs 0.000 claims description 2
- 210000004185 Liver Anatomy 0.000 claims description 2
- 229950000128 Lumiliximab Drugs 0.000 claims description 2
- 108010089988 MDX-1100 Proteins 0.000 claims description 2
- 241001115401 Marburgvirus Species 0.000 claims description 2
- 229950008001 Matuzumab Drugs 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000351643 Metapneumovirus Species 0.000 claims description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 2
- 229950007699 Mogamulizumab Drugs 0.000 claims description 2
- 241001244708 Moroccan pepper virus Species 0.000 claims description 2
- 229960001521 Motavizumab Drugs 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 2
- 108010035649 Natalizumab Proteins 0.000 claims description 2
- 108010019706 Nivolumab Proteins 0.000 claims description 2
- 241000714209 Norwalk virus Species 0.000 claims description 2
- 108010046615 OKT4A monoclonal antibody Proteins 0.000 claims description 2
- 229960002450 Ofatumumab Drugs 0.000 claims description 2
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 claims description 2
- 229950007283 Oregovomab Drugs 0.000 claims description 2
- 108010019613 Palivizumab Proteins 0.000 claims description 2
- 108010061219 Panitumumab Proteins 0.000 claims description 2
- 229950003203 Pexelizumab Drugs 0.000 claims description 2
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 241001505332 Polyomavirus sp. Species 0.000 claims description 2
- 229940071643 Prefilled Syringe Drugs 0.000 claims description 2
- 108010062724 Ranibizumab Proteins 0.000 claims description 2
- 229960003876 Ranibizumab Drugs 0.000 claims description 2
- 241000700157 Rattus norvegicus Species 0.000 claims description 2
- 229960004910 Raxibacumab Drugs 0.000 claims description 2
- 108060006943 RdRp Proteins 0.000 claims description 2
- 241000724205 Rice stripe tenuivirus Species 0.000 claims description 2
- 108010001645 Rituximab Proteins 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 102220460541 SVBP T47D Human genes 0.000 claims description 2
- 229920005654 Sephadex Polymers 0.000 claims description 2
- 239000012507 Sephadex™ Substances 0.000 claims description 2
- 210000000717 Sertoli cell Anatomy 0.000 claims description 2
- 229950008684 Sibrotuzumab Drugs 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 2
- 108010077389 Ustekinumab Proteins 0.000 claims description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 2
- 229950004393 Visilizumab Drugs 0.000 claims description 2
- 241000710886 West Nile virus Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 229950008250 Zalutumumab Drugs 0.000 claims description 2
- 108010058250 abagovomab Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 108010081667 aflibercept Proteins 0.000 claims description 2
- 229960002833 aflibercept Drugs 0.000 claims description 2
- 229960002459 alefacept Drugs 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 108091004612 arcitumomab Proteins 0.000 claims description 2
- 108010072668 atezolizumab Proteins 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229960004669 basiliximab Drugs 0.000 claims description 2
- 108010001114 bavituximab Proteins 0.000 claims description 2
- 108010004485 bectumomab Proteins 0.000 claims description 2
- 229960005347 belatacept Drugs 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000000692 cap cell Anatomy 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- QYJXLKYOBNZROU-UHFFFAOYSA-N carboxysulfonylformic acid Chemical compound OC(=O)S(=O)(=O)C(O)=O QYJXLKYOBNZROU-UHFFFAOYSA-N 0.000 claims description 2
- 201000009030 carcinoma Diseases 0.000 claims description 2
- 101700018328 ccdB Proteins 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 108010004508 clenoliximab Proteins 0.000 claims description 2
- 230000003247 decreasing Effects 0.000 claims description 2
- 229960001251 denosumab Drugs 0.000 claims description 2
- 102000004419 dihydrofolate reductase family Human genes 0.000 claims description 2
- 108020001096 dihydrofolate reductase family Proteins 0.000 claims description 2
- 229960001776 edrecolomab Drugs 0.000 claims description 2
- 108010007604 epratuzumab Proteins 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 108010059577 etaracizumab Proteins 0.000 claims description 2
- 108010012206 galiximab Proteins 0.000 claims description 2
- 108010086781 golimumab Proteins 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 239000004700 high-density polyethylene Substances 0.000 claims description 2
- 101700002672 his-22 Proteins 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 108010067624 labetuzumab Proteins 0.000 claims description 2
- 108010018575 lintuzumab Proteins 0.000 claims description 2
- 108010011366 lumiliximab Proteins 0.000 claims description 2
- 239000012516 mab select resin Substances 0.000 claims description 2
- 108010029633 matuzumab Proteins 0.000 claims description 2
- 108010062313 mepolizumab Proteins 0.000 claims description 2
- 229960005108 mepolizumab Drugs 0.000 claims description 2
- 200000000016 middle east respiratory syndrome Diseases 0.000 claims description 2
- 108010007997 mogamulizumab Proteins 0.000 claims description 2
- 108010031818 monoclonal antibody BIWA 4 Proteins 0.000 claims description 2
- 108010008564 motavizumab Proteins 0.000 claims description 2
- 229960005027 natalizumab Drugs 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 108010045555 obinutuzumab Proteins 0.000 claims description 2
- 229960003347 obinutuzumab Drugs 0.000 claims description 2
- 108010052070 ofatumumab Proteins 0.000 claims description 2
- 108010060422 oregovomab Proteins 0.000 claims description 2
- 229960000402 palivizumab Drugs 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 108010026276 pembrolizumab Proteins 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 108010092042 pemtumomab Proteins 0.000 claims description 2
- 108010042024 pertuzumab Proteins 0.000 claims description 2
- 229960002087 pertuzumab Drugs 0.000 claims description 2
- 108010018063 pexelizumab Proteins 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 2
- 229920001888 polyacrylic acid Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229920001601 polyetherimide Polymers 0.000 claims description 2
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 238000009516 primary packaging Methods 0.000 claims description 2
- 108010087730 raxibacumab Proteins 0.000 claims description 2
- 108010046141 rilonacept Proteins 0.000 claims description 2
- 229960001886 rilonacept Drugs 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 108010043794 sibrotuzumab Proteins 0.000 claims description 2
- 238000004114 suspension culture Methods 0.000 claims description 2
- 108010078548 tocilizumab Proteins 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 210000004881 tumor cells Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 229960003824 ustekinumab Drugs 0.000 claims description 2
- 108010010249 visilizumab Proteins 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 108010023055 zalutumumab Proteins 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims 2
- 108010004463 Abciximab Proteins 0.000 claims 1
- 240000003598 Fraxinus ornus Species 0.000 claims 1
- 241000495102 Maize mosaic nucleorhabdovirus Species 0.000 claims 1
- 229940116542 OTHER NUTRIENTS in ATC Drugs 0.000 claims 1
- 229960000446 abciximab Drugs 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 239000012504 chromatography matrix Substances 0.000 claims 1
- 108091008117 polyclonal antibodies Proteins 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000005755 formation reaction Methods 0.000 abstract description 5
- 101700063973 lgg-1 Proteins 0.000 abstract description 5
- 101700021629 VEMP Proteins 0.000 abstract description 3
- 101700054919 VGE Proteins 0.000 abstract description 3
- 101710026800 lyc Proteins 0.000 abstract description 3
- 101700003508 pgtE Proteins 0.000 abstract description 3
- 108090000288 Glycoproteins Proteins 0.000 abstract description 2
- 102000003886 Glycoproteins Human genes 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 description 16
- 238000006386 neutralization reaction Methods 0.000 description 14
- 230000005591 charge neutralization Effects 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 230000001264 neutralization Effects 0.000 description 13
- 230000035611 feeding Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 108090001095 Immunoglobulin G Proteins 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 8
- 241000702623 Minute virus of mice Species 0.000 description 7
- 241000710829 Dengue virus group Species 0.000 description 6
- 241000714177 Murine leukemia virus Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000007429 general method Methods 0.000 description 6
- 102100009930 PRNT Human genes 0.000 description 5
- 101700059760 PRNT Proteins 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 238000011091 antibody purification Methods 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 235000005824 corn Nutrition 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 108010009736 Protein Hydrolysates Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 238000011143 downstream manufacturing Methods 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229960005486 vaccines Drugs 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000012537 formulation buffer Substances 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011165 process development Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 229940072417 Peroxidase Drugs 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108090000437 Peroxidases Proteins 0.000 description 2
- 210000003501 Vero Cells Anatomy 0.000 description 2
- 239000003011 anion exchange membrane Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 230000001186 cumulative Effects 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000003899 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012092 media component Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000003638 reducing agent Substances 0.000 description 2
- 238000010950 spiking study Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940022659 Acetaminophen Drugs 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 229940041514 Candida albicans extract Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 229940076783 Lucentis Drugs 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N N-tert-butyl-N-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 240000008529 Triticum aestivum Species 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000012523 bacterial endotoxin Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 201000002949 dengue disease Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001124 posttranscriptional Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000001711 protein immunostaining Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Abstract
The invention describes an efficient platform for antibody manufacturing and formulation that provides i) cell culture process with improved feeding strategy resulting in high antibody titer between 2 gm/L to 5 gm/L; ii) improved purification process showing optimal percentage recovery, high purity monomer content, minimum aggregation/particulate formation, minimum impurity levels; and iii) high concentration stable liquid formulation with optimal osmolality and low viscosity across different temperature excursions and devoid of aggregation. The preferred antibodies include lgG1 monoclonal antibody specific to the Dengue virus epitope in domain III of the E protein and lgG1 monoclonal antibody specific to the rabies virus surface G glycoprotein.
Description
IMPROVED METHODS FOR ENHANCING ANTIBODY PRODUCTIVITE IN MAMMALIAN CELL
CULTURE AND MINIMIZING AGGREGATION DURING DOWNSTREAM, FORMULATION
PROCESSES AND STABLE ANTIBODY FORMULATIONS OBTAINED THEREOF
Background of the Invention
Upstream, Downstream and formulation development can often be the rate-limiting step in the early introduction of biopharmaceuticals into clinical trials. For instance, Dengue is the most important mosquito-borne viral disease affecting humans. Half of the world population lives in areas at risk for dengue, resulting in an estimated 390 million infections per year globally. Currently no antiviral agents are approved for treating dengue and recent vaccine trials hâve fallen short of expectations. The leading vaccine candidate recently demonstrated limited efficacy, estimated to be between 30%- 60%, with limited to no significant protection against DENV-2. Recently a non-immunodominant, but functionally relevant, epitope in domain III of the E protein has been identified, and subsequently an engineered antibody, Ab513 is being developed that exhibits high-affinity binding to, and broadly neutralizes, multiple génotypes within ail four serotypes (Refer Ram Sasisekharan et al Cell 162, 1-12, July 30, 2015; Samir Bhatt et al, Nature, 2013 April 25; 496 7446: 504-507). Thus if we consider global medical demand for a Dengue monoclonal antibody, recent estimâtes indicate that up to 390 million dengue infections occur every year globally with >90 million presenting with disease making DENV a major global threat. If we assume that 30% of the 16 million diagnosed dengue cases go to hospital then about 5 million will require said Dengue monoclonal antibody, which implies that “purified antibody” above 4 gm/L becomes a prerequisite to meet global demand of such a life saving antibody. Further, Dengue disease burden is high in developmg countries where availability of electrical power and réfrigération are often inadéquate and therefore antibody stability across température excursions assumes greater relevance for these régions.
Indeed, if it was possible to hâve a platform process that could be employed for manufactunng and formulating ail monoclonal antibody (mAb) candidates it would greatly reduce the time and resources needed for process development. This can hâve a significant impact on the number of clinical candidates that can be introduced into clinical trials. Also, processes developed for early stage clinical trials, including those developed using a platform, may be non-optimal with respect to process économies, yield, pool volumes, throughput and may not be suitable for producing the quantities required for late stage or commercial campaigns. Another important considération is the speed of process development given that process development needs to occur prior to introduction of a therapeutic candidate into clinical trials. (Refer Abhmav A. Shukla et al Journal of Chromatography B, 848 (2007) 28-39).
Typically mammalian cell culture media is based on commercially available media formulations, including, for example, DMEM or Ham's F12. Often media formulations are not sufficiently enriched to support increases in both cell growth and biologie protein expression. There remains a need for improved cell culture media, suppléments, and cell culture methods for improved protein production. Increases in cell culture antibody titers to >2 g/L hâve been reported earlier. Refer F. Wurm, Nat. Biotechnol. 22 (2004) 1393. Further, in perfusion reactors, cells can reach much higher cell densities than in conventional batch or fed-batch reactors. (Refer Sven Sommerfeld et al Chemical Engineering and Processing 44 (2005) 1123-1137). However perfusion based processes are complex, costly and may also resuit in sterility issues and undesired heterogeneity in glycosylation pattern. Addition of animalcomponent-free hydrolysates (Bacto TC Yeastolate, Phytone Peptone) to chemically defined media is a common approach to increase cell density, culture viability and productivity in a timely manner. Hydrolysates are protein digests composed of amino acids, small peptides, carbohydrates, vitamins and minerais that provide nutrient suppléments to the media. Nonanimal derived hydrolysates from soy, wheat and yeast are used commonly in cell culture media and feeds to improve antibody titer (Refer US9284371). However, because of its composition complexity, lot-to-lot variations, undesirable attribute of making culture viscous, Yeast extract and hydrolysates can be a significant source of medium variability. Due to the complexity of antibody products that include isoforms and micro heterogeneities, the performance of the cell culture process can hâve significant effects on product quality and potency, especially with respect to glycosylation, post-transcriptional modifications and impurity profiles.
At higher concentrations, proteins, particularly antibodies often exhibit characteristic problème including aggregation, précipitation, gélation, lowered stability, and/or increased viscosity.
Antibodies are recognized as possessing characteristics that tend to form aggregates and particulates in solution as they undergo dégradation or aggregation or dénaturation or chemical modifications resulting in the loss of biological activity during the manufacturing process and / or during storage with time. Antibody aggregates could be formed during cell culture expression, downstream purification, formulation and on storage. Cell culture harvest usually contains the highest level of aggregate in the process (Refer Deqiang Yu Journal of Chromatography A, 1457 (2016) 66-75). Dégradation pathways for proteins can involve chemical instability (e.g., any process which involves modification of the protein by bond formation or cleavage resulting in a new chemical entity) or physical instability (e.g., changes m the higher order structure of the protein).The three most common protein dégradation pathways are protein aggregation, deamidation and oxidation. Cleland et al Cntical Reviews m
Therapeutic Drug Carrier Systems 10(4): 307-377 (1993). Further, proteins also are sensitive to, for example, pH, ionic strength, thermal stress, shear and interfacial stresses, ail of which can lead to aggregation and resuit in instability. For a protein to remain biologically active, a formulation must therefore preserve intact the conformational integrity of at least a core sequence of the protein’s amino acids while at the same time protecting the protein’s multiple functional groups from dégradation.
A major problem caused by the aggregate formation is that during the administration the formulation may block syringes or pumps and rendering it unsafe to patients. Such protein modifications can also make them immunogenic resulting in the génération of anti-drug antibodies by the patient which can reduce the drug availability during subséquent injections or worse induce an autoimmune reaction. A major aim in the development of antibody formulations is to maintain protein solubility, stability and bioactivity.
Early suggestions about how to solve the problems of instability of protein therapeutics formulations included the lyophilization of the drug product, followed by reconstitution immediately or shortly prior to administration. However, Lyophilized formulations of antibodies hâve a number of limitations, including a prolonged process for lyophilization and resulting high cost for manufacturing. In addition, a lyophilized formulation has to be reconstituted aseptically and accurately by healthcare practitioners prior to administering to patients. The reconstitution step itself requires certain spécifie procedures, i.e. (1) a stérile diluent (i.e., water for intravenous administration and 5% dextrose in water for intramuscular administration) is added to the vial containing lyophilized antibody, slowly and aseptically, and the vial must be swirled very gently for 30 seconds to avoid foaming; (2) the reconstituted antibody may need to stand at room température for a minimum of 20 minutes until the solution clarifies, and (3) the reconstituted préparation must be administered within six (6) hours after the reconstitution. Such reconstitution procedure is cumbersome and the time limitation after the reconstitution can cause a great inconvenience in administering the formulation to patients, leading to significant waste, if not reconstituted properly, or if the reconstituted dose is not used within six (6) hours and must be discarded. Therefore, a liquid formulation is désirable due to factors of clinical and patient convenience as well as ease of manufacture. However liquid pharmaceutical formulations of protein therapeutics, i.e. antibodies should be long-term stable, contain a safe and effective amount of the pharmaceutical compound.
Removal of aggregates is more difficult than removal of process related impurities due to the biophysical similarities between the aggregate and monomer, the multiple sources and types of aggregate, and less understanding of aggregation mechanism.
One of the more recent challenges encountered during formulation development of high concentration monoclonal antibody dosage forms is the formation of proteinaceous subvisible and visible particulates during manufacturing and long-term storage. The level of proteinaceous and non-proteinaceous particulates in IgG formulations is an increasingly important part of purification and formulation development. (Refer Klaus Wuchner et al Journal of Pharmaceutical Sciences, vol. 99, no. 8, august 2010). Further the liquid formulation should be stable across different températures viz températures 2-8° C, 25° C, 40° C , and 55 C.
Many antibody préparations intended for human use require stabilizers to prevent dénaturation, aggregation and other alternations to the proteins prior to the use of the préparation. Previously reported antibody Liquid antibody formulations (Lucentis, Avastin) had mannitol, trehalose as stabilizers. (Refer Susumu Uchiyama et al Biochimica Biophysica Acta 1844 (2014) 20412052; US20160137727; W02009120684; US8568720). However trehalose is costly and not feasible from large scale process économies.
Also, the IV administration of antibody is usually given as an infusion rather than a bolus, and thus requires dilution of mAb formulation, including excipients into appropriate fluids suitable for IV administration. The resulting dilution of excipients, especially surfactants, which may decrease below the concentration required for prévention of aggregation during agitation, thereby resulting in génération of aggregates and subvisible particles following gentle agitation after dilution into PVC and PO IV bags containing 0.9% saline.
Hydrophobie interaction chromatography, ceramic hydroxyapatite and cation exchange resins hâve ail been used for aggregate removal but none are idéal. Majority of previously reported antibody purification processes hâve heavily relied upon use of Hydrophobie interaction chromatography in combination with Protein A chromatography, Anion exchange chromatography, Cation exchange chromatography as a three or four step process (Refer W02010141039 , WO 2014/207763, W02013066707, WO2015099165, W02014102814, WO2015038888, W02004087761). However, Hydrophobie interaction chromatography resins require large amounts of salts that are expensive, show low binding capacity, can be difficult to dispose of, and may not be compatible with the materials of construction of buffer and product holding tanks. Furthermore, the density différence between the buffers used for a HIC step can cause bed stability problems. Ceramic hydroxyapatite can also be used for the séparation of aggregate from monomer, but the ceramic resin can be very difficult to unpack without damaging the resin. Therefore, storing the resin outside the column for re-use in a subséquent manufacturing campaign may not be possible (Refer Suzanne Aldmgton Journal of Chromatography B, 848 (2007) 64-78).
Three-step combinations of cation-exchange, anion-exchange flow through, hydrophobie interaction chromatography and mixed mode cation-exchange chromatography were found to deliver adéquate clearance of host cell protein contaminants for a CHO derived monoclonal antibody. However, such purification schemes by-and-large hâve not caught on in commercial downstream operations due to the need to design the purification sequence separately for each mAb.
Thus, there is an urgent unmet need for an efficient platform process for antibody manufacturing and formulation that meets multiple criterion including robustness, reliability and scalability, in particular a platform that provides i) antibody titer of atleast 2 gm/L; ii) minimum aggregation/particulate formation across cell culture, purification and formulation processes; iii) improved purification showing optimal percentage recovery, high monomer content and minimum impurity levels; and iv) high concentration antibody formulation showing low viscosity,devoid of aggregation and sub-visible particles; thereby showing long-term stability.
Summary of the invention
Applicant has surprisingly found
a) A feed composition and feeding strategy that takes into considération nutrient consumption, by-product accumulation and the balance between promoting growth versus volumétrie productivity wherein in particular, mammalian cell culture process parameters like use of particular basal medium, use of concentrated basal medium as feed solution, use of different feed solutions along-with a definite feeding strategy, maintaining lower concentrations of lactate and ammonia, are found to enhance cell growth, cell longevity and protein expression; thereby resulting in an increased antibody titer.
b) Spécifie sait concentration as part of buffer during Protein A affinity and Cation exchange steps that minimizes aggregation; thereby achieving a monomer content of greater than 99% with a recovery of greater than 80%.
c) Particle free liquid antibody formulations comprising of sucrose in combination with Histidine, Arginine, Polysorbate-80, Sodium chloride that impart higher potency and stability, reduces viscosity of highly concentrated antibody solutions at 2-8°C for at least 9months at 25° C for atleast 1 month, at 40° C for atleast 42 days, at 55° C for atleast 2 days as compared to formulation devoid of sucrose.
List of Figures:
1. Figure 1 : Flow chart - Downstream processing for purification of monoclonal antibody
2. Figure 2 : Flow chart - Formulation process for monoclonal antibody
Description of the invention
Therapeutic proteins of the présent invention include, but are not limited to antigen binding protein, humanized antibody, chimeric antibody, human antibody, bi-specific antibody, multivalent antibody, multi-specific antibody, antigen binding protein fragments, polyclonal, monoclonal, diabodies, nanobodies, monovalent, hetero-conjugate, multi-specific, autoantibodies, single chain antibodies, Fab fragments, F(ab)'2, fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-ld) antibodies, epitope-binding fragments and CDR-containing fragments or combination thereof.
In an embodiment of the présent invention, the therapeutic protein is an antigen binding protein or immunoglobulin; more preferably is an IgG and most preferably is an lgG1 molécule. In first aspect of the présent embodiment, immunoglobulin/antibody is a human lgG1 (G1m3 allotype) with a human kappa light chain spécifie to the Dengue virus epitope in domain III of the E protein. In second aspect of the présent embodiment, the antibody is a fully human lgG1 monoclonal antibody spécifie to the rabies virus surface G glycoprotein. In third aspect of the présent embodiment, the therapeutic protein can be selected from the group comprising of CTP19 , CR57 , CR4098, RVFab8, MabJA, MabJB-1, Mab 57.17C7, 2B10, Ab513/VIS513, N297Q-B3B9 , Mab2E8 , 2D22, DMScHuMab, 3CH5L1, HMB DV5, HMB DV6, HMB DV8, DB32-6, D88, F38, A48, C88, F108, B48, A68, A100, C58, C78, C68, D98, D188, C128, C98, A11, B11, R17D6, R14B3, R16C9, R14D6, R18G9, R16F7, R17G9, R16E5 , antibodies derived from modification of 4E11A,adatacept, abeiximab, adalimumab, aflibercept, alefacept, alemtuzumab.trastuzumab, basiliximab, bevacizumab, belatacept, bectumomab, certolizumab, cetuximab, daclizumab, eculizumab, efalizumab, entanercept, gemtuzumab, ibritumomab, infliximab, muromonab-CD3, omalizumab, palivizumab; panitumumab, pertuzumab, ranibizumab, rilonacept, rituximab, tositumomab, trastuzumab, zanolimab, nivolumab, pembrolizumab ,hA20, AME-I33, IMC-3G3, zalutumumab, nimmotuzumab, matuzumab, ch*)A, KSB-102, MR1-1, SC100, SC101, SC103, muromonab-CD3, OKT4A, ibritumomab, gemtuzumab, motavizumab, infliximab, pegfilgrastin, CDP-571, etanercept, ABX-CBL , ABXIL8, ABX-MAI pemtumomab, Therex, AS1405, natalizumab, HuBC-l, IDEC-131, VLA-I; CAT152; J695, CAT- 192, CAT-213, BR3-Fc, LymphoStat-B, TRAIL-RImAb , bevacizumab, omalizumab, efalizumab, MLN-02, HuMax-IL 15, HuMax-Inflam, HuMax-Cancer, HuMaxLymphoma, HuMax-TAC, clenoliximab, lumiliximab, BEC2, IMC-ICI 1, DCIOI, labetuzumab, arcitumomab, epratuzumab, tacatuzumab, Cetuximab, MyelomaCide, LkoCide, ProstaCide, ipilimumab, MDX-060, MDX-070, MDX-018, MDX-1106, MDX-1103, MDX-1333, MDX-214, MDX-1100, MDX-CD4, MDX- 1388, MDX-066, MDX-1307, HGS-TR2J, FG-3019, BMS-66513, SGN-30, SGN-40, tocilizumab, CS-1008, IDM-I, golimumab, CNTO 1275, CNTO 95, CNTO 328, mepolizumab, MORIOI, MORI 02, MOR201, visilizumab, HuZAF, volocixmab, ING-I, MLN2201, daclizumab, HCD 122, CDP860, PRO542, C 14, oregovomab, edrecolomab, etaracizumab, atezolizumab ,iplimumab,mogamulizumab, lintuzumab, HulDIO, Lym-1, efalizumab, ICM3, galiximab, eculizumab, obinutuzumab,pexelizumab, LDP-OI, huA33, WXG250, sibrotuzumab, ofatumumab, Chimeric KW-2871, hu3S193, huLK26;
bivatuzumab.raxibacumab, chl4.18, 3F8, BC8, huHMFGI, MORAb-003, MORAb-004, MORAb009, denosumab, PRO-140, 1D09C3, huMikbeta-1, NI-0401, NI-501, cantuzumab, HuN901, 8H9, chTNT-1/B, bavituximab, huJ591, HeFi-l, Pentacea, abagovomab, tositumomab, ustekinumab,105AD7, GMAI 61, GMA321.
In other aspect of this embodiment, therapeutic protein is an antibody having binding affinity towards epitopes présent on Dengue virus, Rabies virus, RSV, MPV, Influenza virus, Zika virs, West Nile virus,Yellow fever virus, chikungunya virus, HSV, CMV, MERS, Ebola virus, EpsteinBarr virus, Varicella-Zoaster virus, mumps virus, measles virus, polio virus, rhino virus, adenovirus, hepatitis A virus, Hepatitis B virus, hepatitis C virus, Norwalk virus, Togavirus, alpha virus, rubella virus, HIV virus, Marburg virus, Ebola virus, Human pappiloma virus, polyoma virus, metapneumovirus, coronavirus, VSV and VEE.
In another aspect of this embodiment, isoelectric point (pl) of said antigen binding protein is 7.0 - 8.5, more preferably about 7.4 to about 8.2.
In particular, the antigen binding protein is a therapeutic, prophylactic or diagnostic antibody as described in WO2014025546, WO2015122995, WO2015123362, W02006084006,
W02017027805 and WO2017165736, the contents of which are incorporated herein by reference in its entirety. More preferably, therapeutic protein is an antibody having 80% similarity to that VIS513 (Seq ID 1 or Seq ID 2). In other preferred aspect of the présent embodiment, therapeutic protein is an antibody having more than 80% similarity to that of rabies monoclonal antibody (Seq ID 3 and Seq ID 4).
It is very well understood that any host may be used for the expression of therapeutic protein m the methods described herein. The cells may be wild or genetically engineered to contain a recombinant nucleic acid sequence, e.g. a gene, which encodes a polypeptide of interest (e.g., an antibody).
In second embodiment of the présent invention, cell line used for the expression of therapeutic proteins is selected from the group including but not limited to CHO, CHOK1SV GS-KO, GSCHO, CHO DUX-B11, CHO-K1, BSC-1, NSO myeloma cells, CV-1 in Origin carrying SV40 (COS) cells, COS-1, COS-7, P3X3Ag8.653, C127, 293 EBNA, MSR 293, Colo25, U937, SP2 cells, L cell, human embryonic kidney (HEK 293) cells, baby hamster kidney (BHK 21) cells, African green monkey kidney VERO-76 cells, HELA cells, VERO, BHK, MDCK, WI38 cells, NIH-3T3, W138, BT483, Hs578T, HTB2, BT20, T47D, NSO (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, HsS78Bst cells, PER.C6, SP2/0-Ag14, a myeloma cell line, a hybridoma cell line, human lung cells (W138), Retinal cells, human hepatoma line (Hep G2), and hybridoma cells.
In other aspect of the second embodiment, animal or mammalian host cells includes but not limited to Chinese hamster ovary cells (CHO) such as CHO—K1 (ATCC CCL-61), DG44 (Chasin et al., 1986, Som. Cell Molec. Genet., 12:555-556; and Kolkekar et al., 1997, Biochem., 36:10901-10909), SH87 cellCHO-DXB11 (G. Urlaub and L. A. Chasin, 1980 Proc. Natl. Acad. Sci., 77: 4216-4220. L. H. Graf, and L. A. Chasin 1982, Molec. Cell. Biol., 2: 93-96), CHO—K1 Tet-On cell line (Clontech), CHO designated ECACC 85050302 (CAMR, Salisbury, Wiltshire, UK), CHO clone 13 (GEIMG, Genova, IT), CHO clone B (GEIMG, Genova, IT), CHO—K1/SF designated ECACC 93061607 (CAMR, Salisbury, Wiltshire, UK), RR—CHOK1 designated ECACC 92052129 (CAMR, Salisbury, Wiltshire, UK), CHOKIsv (Edmonds et al., Mol. Biotech. 34:179-190 (2006)), CHO—S (Pichler et al., Biotechnol. Bioeng. 108:386-94 (2011)), dihydrofolate reductase négative CHO cells (CHO/-DHFR, Urlaub and Chasin, 1980, Proc. Natl. Acad. Sci. USA, 77:4216), and dp12.CHO cells (U.S. Pat. No. 5,721,121); monkey kidney CV1 cells transformed by SV40 (COS cells, COS-7, ATCC CRL-1651), human embryonic kidney cells (e.g., 293 cells, or 293 cells subcloned for growth in suspension culture, Graham et al., 1977, J. Gen. Virol·, 36:59); baby hamster kidney cells (BHK, ATCC CCL-10); CAP cell, AGE1.HN cell, monkey kidney cells (CV 1, ATCC CCL-70); African green monkey kidney cells (VERO-76, ATCC CRL-1587; VERO, ATCC CCL-81); mouse sertoli cells (TM4, Mather, 1980, Biol. Reprod., 23:243-251); human cervical carcinoma cells (HELA, ATCC CCL2); canine kidney cells (MDCK, ATCC CCL-34); human lung cells (W138, ATCC CCL-75); human hepatoma cells (HEP-G2, HB 8065); mouse mammary tumor cells (MMT 060562, ATCC CCL-51); buffalo rat liver cells (BRL 3A, ATCC CRL-1442); TR1 cells (Mather, 1982, Ann. NY Acad. Sci., 383:44-68); MCR 5 cells; and FS4 cells.
In first aspect of the second embodiment, cell line used for the expression of therapeutic proteins is Chinese Hamster Ovary cells; more particularly the cell line is CHOK1SV GS-KO or
GS-CHO.
In third embodiment of the présent invention, the cells are cultivated in a batch, fed batch or continuous mode; more particularly in a fed batch mode. It is very well understood, that a person skilled in the art can modulate a process described in this invention according to available facilities and individual needs. More particularly, the cell culture process is carried out in fed batch mode providing enhanced cell growth, cell longevity and increased protein expression i.e. provides a harvest yield of atleast 2 gm/L, preferably in the range of 3 gm/L to about 6 gm/L.
In first aspect of the third embodiment, cell culture is conducted in a flask, a bioreactor, a tank bioreactor, a bag bioreactor or a disposable bioreactor. Preferably said bioreactor is selected from the group of stirred tank bioreactor, a bubble column bioreactor, an air lift bioreactor, a fluidized bed bioreactor or a packed bed bioreactor; and the said bioreactor has a volume selected from 1L, 2L, 3L, 5L, 10L, 20L, 100L, 200L, 250L, 350L, 500 L, 1000L, 1500L, 3000L, 5000L, 10000L , 20000L and 30,000 liters.
In second aspect of the third embodiment, the présent cell culture media and methods may be used to increase antibody yield by about 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 180%, or 200% , most preferably about 40% to 60% as measured over a course of a fortnight. The time period of the fed batch method can be about 12 to 20 days; about 15 to 20 days or about 15 to 18 days.
In fourth embodiment of the présent invention, cell culture medium is selected from the group comprising one or more of CD CHO, CD OptiCHO™, CD FortiCHO™ (Life Technologies), ExCell™ CD CHO (Sigma Aldrich); ProCHO™5 (Lonza); BalanCD™ CHO Growth A (Irvine Scientific); CDM4Mab(Hyclone); Cellvento™ CHO-100 (EMD Millipore); Cell vento 200 (Merck Millipore); Cell vento 220 (Merck Millipore); Actipro (Hyclone); and combination thereof. Preferably the cell culture medium is selected from Cell Vento 220 (Merck), ACTIPRO (HyClone/GE), or Gibco™ Dynamis™ Medium (Thermo Fisher).
The cell culture medium is further supplemented with glucose and other feed solutions so as to increase cell growth, cell longevity, protein expression and yield. It is very well understood in the art that the feed solutions may be supplemented in rapid bolus or graduai drip manner.
The supplémentation of feed solution in cell culture medium with a feeding strategy comprising of:
Initial feeding with Feed solution A, at 0.05% to 0.5% reactor volume, preferably at 0.1% to 0.2% reactor volume, from day 4;
Feeding with Feed solution A, at 0.1% to 0.5% reactor volume on day 6, 8, 10,11 and 13;
Feed solution B at less than 8% reactor volume, from day 2 to day 14, on alternate day or in continuons manner;
Feeding with Feed solution C at less than 8% reactor volume for atleast 2 consecutive days beginning from day 2 or day 3, having an intermittent gap of 2 consecutive days, till day 12th or day 14th or day 15th or day 16th or day 18th.
Feeding with Feed solution D at less than 0.5% reactor volume for atleast 2 consecutive days beginning from day 4 or day 5, on alternate day or in continuous manner or having an intermittent gap of 2 consecutive days, till day 12th or day 14th or day 15th or day 16th or day 18th. Optionally feeding atleast one feed solution selected from EfficientFeed™ A, EfficientFeed™ B, EfficientFeed™ C, and Dow corning Antifoam C.
In a preferred aspect of fourth embodiment, said Feed solution A, Feed solution B, Feed solution C, Feed solution D is selected one or more from group comprising of Glucose, Cell Boost™ 5 Supplément (Hyclone), EX-CELL 293 (Sigma Aldrich), Cell Boost 7a and 7b suppléments (Hyclone), 3X Actipro (Hyclone/GE), Cell Vento 220 (1X medium), EX-CELL® Advanced™ CHO Feed 1, EfficientFeed™ A, EfficientFeed™ B, and EfficientFeed™ C, and combination thereof.
In a most preferred aspect of the fourth embodiment, said Feed solution A is Cell Boost™ 5 Supplément (Hyclone); Feed solution B is EX-CELL 293 (Sigma Aldrich), Feed solution C is Cell Boost 7a suppléments (Hyclone), Feed solution D is Cell Boost 7b suppléments (Hyclone). Further, the cell culture medium is supplemented with 10% “3X Actipro” (Hyclone) on 3rd day and 8% Cell Vento 220 (1X medium) on 7th day of cell culturing. It is very well understood that ail the feedings addition can vary by ± 1% and ± 1 day by a person skilled in the art.
Another aspect of the fourth embodiment includes cell culture conditions employed for increasing the cell growth and longevity and protein expression. The following cell culture conditions employed during the process includes but not limited to.
pH of cell culture medium is in the range of 6.5 and 7.5;
Osmolality of the culture medium is in the range of 250 - 500 mOsm/kg; more preferably 400 - 500 mOsm/kg.
Dissolved oxygen is in the range of 10 - 60%; preferably 20-40%; more preferably 30/o.
Cell culture température is in the range of 30°C to 38°C; first température preferably 36 - 37 °C and optionally second température preferably 30 — 35 C.
Glucose concentration is maintained below 7%; preferably between 4% and 5%.
Harvesting the cell culture when viability is decreased to 80 %;
Wherein the cell culture conditions are maintained in a manner that secondary métabolites such as Lactate concentration is not more than 5g/L; and Ammonia concentration is not more than 5 mMol/L
In fifth embodiment of the présent invention, the said therapeutic protein obtained from the cell culture harvest is subjected to a purification process comprising of following steps i) affinity chromatography, ii) Viral inactivation, iii) ion exchange chromatography, and iv) filtration; wherein the overall process recovery is more than 70% and the final purified therapeutic protein has a purity/monomer content of atleast 90%, preferably more than 98%. Other impurities including residual cell DNA, residual cell protein, and residual protein A in final purified therapeutic protein is less than 1%.
In general aspect of the fifth embodiment, the inventors of this invention hâve succeeded in dealing with problem of aggregation of therapeutic protein during downstream processing of the said protein, by using i) Sait in a affinity chromatography wash step and ii) Linear gradient of sait solution for elution in ion exchange chromatography step. In preferred aspect of the said embodiment, the sait concentration of the buffers used in purification is in the range of 30 mM - 500 mM, more preferably the sait concentration of the buffers used in purification is in the range of 50 mM - 300 mM.
In first aspect of the fifth embodiment, affinity chromatography selected from the group comprising one or more of Protein A chromatography, Protein G chromatography, Protein L chromatography, and combination thereof; preferably the affinity chromatography used is Protein A chromatography.
In second aspect of the fifth embodiment, resin used for Protein A chromatography is selected from the group comprising one or more of Eshmuno A, KanCapATM, MabSelect SuRe™, MabSelect SuRe LX, MabSelect Xtra, rProtein A Sepharose Fast Flow, Poros® MabCapture A, Amsphere™ Protein A JWT203, ProSep HC, ProSep Ultra, and ProSep Ultra Plus; Preferrably the Protein A affinity chromatography resin is MabSelect SuRe™, Eshmuno A, Kancap A or Poros MabCapture; more preferably the Protein A affinity chromatography resin is MabSelect SuRe™.
In third aspect of the fifth embodiment, the wash buffer used for Protein A chromatography is selected from the group comprising one or more of
- 30 mM Phosphate buffer, preferably 20 mM Phosphate buffer; 100 - 150 mM NaCI, preferably 150 mM NaCI; 0.05% Polysorbate 80; pH 7.0 ± 0.2.
- 30 mM Phosphate buffer, preferably 20 mM Phosphate buffer; 250 mM - 1 M NaCI, preferably 1M NaCI; 0.05% Polysorbate 80; pH 7.0 ± 0.2.
- 30 mM Phosphate buffer, preferably 10 mM Phosphate buffer; 100 - 150 mM NaCI, preferably 125mM NaCI; 0.05% Polysorbate 80; pH 7.0 ± 0.2.
In fourth aspect of the fifth embodiment, elution buffer used for Protein A chromatography comprises of 10 - 30 mM Citrate buffer; pH 3.0 ± 0.5; and optionally 0.01 - 0.05 % (w/v) Polysorbate 80; preferably the elution buffer comprises of 20mM Citrate buffer; pH 3.0 ± 0.2; and optionally 0.025 % (w/v) Polysorbate 80.
In fifth aspect of the fifth embodiment, eluate obtained from the affinity chromatography step is subjected to viral inactivation and réduction. It is very well understood in the art that viral inactivation and réduction of the eluate may be effected by method selected individually or in combination from the group comprising of pH treatment, detergent treatment, heat treatment, and virus réduction filtration. In preferred aspect of this embodiment, the viral inactivation is effected by subjecting the eluate to low pH i.e. 3.3 — 3.5 for 50 — 100 minutes. Further, the eluate was pH neutralized by subjecting it to neutralization buffer i.e. 1 M Tris/Citrate buffer pH 7.0 ± 0.2. It is very well understood in the art that any other compatible buffer may be used alternatively for effective pH neutralization of the eluate.
In sixth aspect of the fifth embodiment, the viral inactivated eluate is subjected to ion exchange chromatography. According to one of the aspect of this embodiment, ion exchange chromatography is cation exchange chromatography or anion exchange chromatography or their combination; and chromatography may be carried out in “bind and elute” mode or “flow through” mode. In preferred aspect of this embodiment, cation exchange chromatography and anion exchange chromatography is carried out in any sequential order. A further aspect of the fifth embodiment is that the said chromatography resin optionally is a multi-modal resin like Capto MMC resin (GE Healthcare).
In seventh aspect of the fifth embodiment, the viral inactivated eluate is subjected to cation exchange chromatography. In preferred aspect of this embodiment, the chromatography parameters including chromatography resin and buffer conditions are selected in such a manner that the positively charged therapeutic protein binds to the chromatography resin while the negatively charged molécules cornes in the flow through, further therapeutic proteins are subjected to elution using a sait gradient. In preferred aspect of this embodiment, the cation exchange chromatography resin is selected from the group comprising one or more of sulfonate based group (e.g., MonoS, MiniS, Source 15S and 30S, SP SEPHAROSE® Fast Flow, SP SEPHAROSE® High Performance from GE Healthcare, TOYOPEARL® SP-650S and SP-650M from Tosoh, MACRO-PREP® High S from BioRad, Ceramic HyperD S, TRISACRYL® M and LS SP and Spherodex LS SP from Pall Technologies); a sulfoethyl based group (e.g., FRACTOGEL® SE, from EMD, POROS® S-10 and S-20 from Applied Biosystems); a sulphopropyl based group (e.g., TSK Gel SP 5PW and SP-5PW- HR from Tosoh, POROS® HS-20, HS 50, and POROS® XS from Life Technologies); a sulfoisobutyl based group (e.g., FRACTOGEL® EMD S03 from EMD); a sulfoxy ethyl based group (e.g., SE52, SE53 and Express-Ion S from Whatman), a carboxymethyl based group (e.g., CM SEPHAROSE® Fast Flow from GE Healthcare, Hydrocell CM from Biochrom Labs Inc., MACRO-PREP® CM from BioRad, Ceramic HyperD CM, TRISACRYL® M CM, TRISACRYL® LS CM, from Pall Technologies, Matrex CELLUFINE® C500 and C200 from Millipore, CM52, CM32, CM23 and Express-Ion C from Whatman, TOYOPEARL® CM-650S, CM-650M and CM-650C from Tosoh); sulfonic and carboxylic acid based groups (e.g., BAKERBOND® Carboxy-Sulfon from J.T. Baker); a carboxylic acid based group (e.g., WP CBX from J.T Baker, DOWEX® MAC-3 from Dow Liquid Séparations, AMBERLITE® Weak Cation Exchangers, DOWEX® Weak Cation Exchanger, and DIAION® Weak Cation Exchangers from SigmaAldrich and FRACTOGEL® EMD COO- from EMD); a sulfonic acid based group (e.g., Hydrocell SP from Biochrom Labs Inc., DOWEX® Fine Mesh Strong Acid Cation Resin from Dow Liquid Séparations, UNOsphere S, WP Sulfonic from J.T. Baker, SARTOBIND® S membrane from Sartorius, AMBERLITE® Strong Cation Exchangers, DOWEX® Strong Cation and DIAION® Strong Cation Exchanger from Sigma-Aldrich); and a orthophosphate based group (e.g., PI 1 from Whatman). In most preferred aspect of this embodiment, the resin used for cation exchange chromatography is Fractogel® EMD SO3“, Fractogel® EMD SE Hicap (Merck), CMM HyperCel™ (Pall Corporation), Capto S ImpAct. In another aspect of fifth embodiment, process parameters for cation exchange chromatography includes but not limited t0 Pre-equilibration buffer [200 mM Citrate buffer; pH 6.0 ± 0.2]; Equilibration buffer [10 mM Citrate buffer; Polysorbate 80 (0.025 % (w/v)); pH 6.0 ± 0.2]; Low pH hold for neutralization, Wash Buffer A [10 mM Citrate buffer; pH 6.0 ± 0.2]; Wash buffer B [20 mM Citrate buffer, 300 500 mM NaCI; pH 6.0 ± 0.2]; CIP buffer [0.5M NaOH]; Résidence time [4.00 - 7.00 minutes];
Column used [XK26].
In eighth aspect of the fifth embodiment, the viral inactivated eluate is subjected to amon exchange chromatography. In preferred aspect of this embodiment, the chromatography parameters including chromatography resin and buffer conditions are selected in such a manner that ail negatively charged impurities are bound with the membrane while the therapeutic protein elutes in a flow through. In preferred aspect of this embodiment, the amon exchange chromatography resin is selected from the group comprising one or more of DEAE cellulose, POROS® PI 20, PI 50, HQ 10, HQ 20, HQ 50, D 50 from Applied Biosystems,
SARTOBIND® Q from Sartorius, MonoQ, MiniQ, Source 15Q and 30Q, Q, DEAE and ANX SEPHAROSE® Fast Flow, Q SEPHAROSE, Q SEPHAROSE® High Performance, QAE SEPHADEX® and FAST Q SEPHAROSE® (GE Healthcare),WP PEI, WP DEAM, WP QUAT from J.T. Baker, Hydrocell DEAE and Hydrocell QA from Biochrom Labs Inc., U Osphere Q, MACRO-PREP® DEAE and MACRO-PREP® High Q from Biorad, Ceramic HyperD Q, ceramic HyperD DEAE, TRISACRYL® M and LS DEAE, Spherodex LS DEAE, QMA SPHEROSIL® LS, QMA SPHEROSIL® M and MUSTANG® Q from Pall Technologies, DOWEX® Fine Mesh Strong Base Type I and Type II Anion Resins and DOWEX® MONOSPHER E 77, weak base anion from Dow Liquid Séparations, INTERCEPT® Q membrane, Matrex CELLUFINE® A200, A500, Q500, and Q800, from Millipore, FRACTOGEL® EMD TMAE, FRACTOGEL® EMD DEAE and FRACTOGEL® EMD DMAE from EMD, AMBERLITE® weak strong anion exchangers type I and II, DOWEX® weak and strong anion exchangers type I and II, DIAION®weak and strong anion exchangers type I and II, DUOLITE® from Sigma-Aldrich, TSK gel Q and DEAE 5PW and 5PW-HR, TOYOPEARL® SuperQ-650S, 650M and 650C, QAE-550C and 650S, DEAE-650M and 650C from Tosoh, QA52, DE23, DE32, DE51, DE52, DE53, Express-Ion D and Express- Ion Q from Whatman; more preferably Anion-exchange chromatography resin is selected from Sartobind Q (Sartorius), Eshmuno Q (Merck), MUSTANG® Q (Pall Corporation) and Poros X (Thermo). In another aspect of fifth embodiment, process parameters for anion exchange chromatography includes but not limited to Cleaning buffer [0.5M NaOH]; Pre-equilibration buffer [200 mM Citrate buffer; pH 6.0 ± 0.2]; Equilibration buffer [20 mM Citrate buffer; pH 6.0 ± 0.2; and optionally 0.025% Polysorbate 80]; Storage buffer [0.1 M NaOH]; Linear Flow rate [10 - 500 cm/hr, more particularly 100-150 cm/hr]; Column used [XK26],
The purification process of aforementioned embodiments can further comprise of atleast one additional chromatography step selected from the group comprising one or more of Hydrophobie interaction chromatography, Hydrophobie charge induction chromatography, Ceramic hydroxyapatite chromatography, Multimodal chromatography (Capto MMC and Capto Adhéré), Membrane chromatography (Q membranes including Intercept™ (Millipore), Mustang® (Pall Corporation) and Sartobind™ (Sartorius)).
In ninth aspect of the fifth embodiment, virus particles were removed by using 20 nm filter. The filter used for removal of viral particles includes but not limited to virus retentive filter selected from the group of Viresolve PRO (Merck), Planova 20N (Asahi Kasei), Bio EXL PALL PEGASUS PRIME, PEGASUS SV4 (Pall Life Sciences), and Virosart (Sartorius), Virosart CPV filter from Sartorius, Virosolve from Millipore, Ultipor DV20 or DV50 from Pall, Planova 20N and 50N or BioEx from Asahi. It is very well understood in the art that any other filter having rétention capacity for viruses may be used in this step; preferably the filter used for removal of viral particles is selected from Viresolve PRO (Merck), Bio EXL PALL PEGASUS PRIME,
PEGASUS SV4 (Pall Life Sciences), and Virosart (Sartorius).
In tenth aspect of the fifth embodiment, the therapeutic protein is concentrated to a desired concentration and buffer exchanged in formulation buffer. The buffer is exchanged in a tangential flow filtration System or an ultra flow filtration System. The other parameters of Tangential flow filtration comprises of one or more selected from Diafilteration using diafilteration buffer [25 mM Histidine buffer; 75 mM Arginine buffer; 50- 150 mM NaCI; pH 6.50 ± 0.5]; Cleaning buffer [0.5M NaOH]; Storage buffer [0.1M NaOH]; Equilibration using 5 - 10 X membrane volume; Concentration and Diafilteration using 10-20 diafilteration volume; WFI wash using 3-5 membrane volume; cleaning using 0.5 - 1.0 M NaOH; Storage [0.1M NaOH], In one ofthe preferred aspect of this embodiment, Tangential flow filtration is carried out using 30 kDa MWCO membrane selected from the group comprising one or more of Centramate T sériés PES membrane (Pall Corporation), Hydrosart (Sartorius), and Pelicon 3 (Merck).
In sixth embodiment ofthe présent invention, the said purified therapeutic protein is formulated with pharmaceutical excipients, wherein the osmolality of the formulation is in the range of 300 mOsm/Kg to 500 mOsm/Kg and viscosity ofthe formulation is less than 2.5 mPa-S.
In first aspect ofthe sixth embodiment, therapeutic protein formulation comprises of atleast one antigen binding protein, atleast one stabilizer, atleast one buffering agent, atleast one tonicity agent, and atleast one surfactant. Optionally, formulation comprises of a preservative.
In second aspect of the sixth embodiment, stabilizer is an carbohydrate. Stabilizer is selected from the group comprising of one or more of sucrose, sorbitol, trehalose, mannitol, dextran, inositol, glucose, fructose, lactose, xylose, mannose, maltose, Raffinose and combination thereof; more preferably the stabilizer is sucrose. In yet another aspect of this embodiment, stabilizer comprises of sucrose at a concentration of about 0.1% to about 2.5% w/v, preferably <1% sucrose w/v.
In third aspect of the sixth embodiment, buffering agent is selected from the group comprising of one or more of histidine, arginine, glycine, sodium citrate, sodium phosphate, citric acid, HEPES, potassium acetate, potassium citrate, potassium phosphate, sodium acetate, sodium bicarbonate, Tris base, or Tris-HCI, and combination thereof. Preferably, buffering agent provides a pH of about 5.5 to 7.5, about 6.0 to 7.0, about 6.3 to about 6.8, or about 6.5
In fourth aspect of sixth embodiment, buffering agent is Histidine. In preferred aspect of this embodiment, the buffering agent comprises Histidine at a concentration of about 5 mM to about 150 mM, about 10 mM to about 50 mM, about 20 mM to about 40 mM. In most preferred aspect of this embodiment, buffering agent comprises Histidine at a concentration of about 25 mM.
In fifth aspect of sixth embodiment, buffering agent is Arginine. In preferred aspect of this embodiment, the buffering agent comprises Arginine at a concentration of about 5 mM to about 200 mM, about 50 mM to about 150 mM, about 50 mM to about 100 mM. In most preferred aspect of this embodiment, buffering agent comprises Arginine at a concentration of about 70 to 80 mM.
In sixth aspect of sixth embodiment, tonicity agent is selected from the group comprising of one or more of sodium chloride, dextrose, glycerin, mannitol, and potassium chloride. In preferred aspect of this embodiment, tonicity agent comprises of Sodium Chloride and is présent at a concentration of about 10 mM to about 500 mM; preferably at concentration of about 50 mM to about 250 mM; most preferably at a concentration of about 100 - 145 mM.
In seventh aspect of sixth embodiment, surfactant is présent at a concentration of about 0.001 to about 0.2%(w/v); and is selected from the group comprising of one or more of polysorbates (e.g. polysorbate- 20 or polysorbate-80); poloxamers (e.g. poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium laurel sulfate; sodium octyl glycoside, lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g. lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine, sodium methyl cocoyl-, or disodium methyl oleyl-taurate; and the MONAQUAT® sériés (Mona Industries, Inc., Paterson, N.J.), polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g. Pluronics, PF68 etc). In preferred aspect of this embodiment, surfactant comprises of Polysorbate 80 and is présent at a concentration of about 0.001 /□ to about 0.2% w/v; preferably at concentration of about 0.002% to about 0.02%; about 0.005% to about 0.02%, most preferably at a concentration of about 0.02%.
In eighth aspect of sixth embodiment, the formulation comprises of a therapeutic protein at a concentration of about 1mg/L to about 150 mg/L, about 1mg/L to about 50 mg/L, about 20 mg/L to about 40 mg/L. Preferably the formulation comprises of a therapeutic protein at a concentration of about 1mg/L to about 50 mg/L.
In ninth aspect of the sixth embodiment, the formulation further comprises of preservative, the preservative may be selected from the group comprising of benzyl alcohol, m-cresol, and phénol.
In seventh embodiment of the présent invention, the therapeutic protein formulation comprises of atleast one therapeutic protein, sucrose, arginine, histidine, Sodium chloride, Polysorbate 80. Preferably therapeutic protein formulation comprises of about 1 mg/ml to about 50 mg/ml of therapeutic protein; about 20 mM to about mM mg/ml of Histidine; about 50 mM to about 100mM of Arginine; about 0.002% to about 0.02% Polysorbate 80 (w/v); about 50 mM to about 150 mM NaCI; and <2.5% Sucrose w/v. The pH of the formulation is in the range of 6.0 to about 7.0 and Osmolality of the formulation is in the range of 300 mOsm/Kg to about 450 mOsm/Kg.
In one of the preferred aspect of seventh embodiment, a pharmaceutical formulation comprises of 2 - 80 mg/ml of Dengue monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
In one of the preferred aspect of seventh embodiment, a pharmaceutical formulation comprises of 25 mg/ml of Dengue monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 ,Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
In one of the preferred aspect of seventh embodiment, a pharmaceutical formulation comprises of 50 mg/ml of Dengue monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
In one of the preferred aspect of seventh embodiment, a pharmaceutical formulation comprises of 2 - 80 mg/ml of Rabies monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
In one of the preferred aspect of seventh embodiment, a pharmaceutical formulation comprises of 25 mg/ml of Rabies monoclonal antibody; 25 mM of Histidine; 75 mM of
Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
A pharmaceutical formulation comprising of 50 mg/ml of Rabies monoclonal antibody; 25 mMof Histidine; 75 mMof Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
According to another aspect of the seventh embodiment, said pharmaceutical formulation of antibody could be a lyophilized formulation.
In eighth embodiment of the présent invention, the affinity and potency of the therapeutic protein is measured by one or more of ELISA or flow cytometry. In preferred aspect of the eighth embodiment, indirect ELISA based method is used to quantify binding of therapeutic protein to the spécifie antigen. In preferred aspect of this embodiment, Dengue Mab formulation is tested against ail serotypes of the dengue viruses and amount of Dengue mAb is determined. The potency of the therapeutic protein is reported as % activity relative to the référencé standard. It is very well understood that any other similar method may be used to demonstrate the potency and affinity of the therapeutic protein.
In ninth embodiment of the présent invention, focus réduction neutralization test (PRNT / FRNT) or a related test is carried out for evaluating neutralization of viral activity by therapeutic protein. In preferred aspect of this embodiment, Dengue mAb formulation is tested against ail serotypes of the dengue viruses and EC50 values are calculated for neutralization of Dengue Viruses. It is very well understood that any other similar method may be used to demonstrate the neutralization activity of the therapeutic protein.
In tenth embodiment of the présent invention, HPLC based size exclusion chromatography is used to assess the presence of aggregates in therapeutic protein formulation. In preferred aspect of this embodiment, Phenomenex Bio-Sec-S 3000 column is used to demonstrate the aggregate and monomer percentage of Dengue mab formulation. It is very well understood that any other similar method may be used to assess the presence of aggregates in therapeutic protein formulation.
ln e|eventh embodiment of the présent invention, the formulation may be stored in a suitable container. The container may be selected from a bottle, a vial, a glass vial, a IV bag, a form/blow-fill seal container, a wearable injecter, a bolus injector, a syringe, a pen, a pump, a multidose needle syringe, a multidose pen, a injector, a syrette, an autoinjector, a prefilled syringe, or a combination thereof.
At least one primary packaging component comprises a container closure selected from polypropylene (PP), polyethylene terephthalate (PETG), high-density polyethylene (HDPE), polyethylene terephthalate (PET), polypentafluorostyrene (PFS), polycarbonate, polyvinyl chloride (PVC), polyolefin, polycyclopentane (CZ.RTM.), cyclic olefin copolymer (CGC), and combinations or copolymers thereof.
The anti-dengue antibody or anti-rabies antibody formulations disclosed herein can be used (alone or in combination with other agents or therapeutic modalities) to treat, prevent and or diagnose dengue or rabies virus. For example, the combination therapy can include an antidengue antibody molécule co-formulated with, and/or co-administered with, one or more additional therapeutic agents, e.g., antiviral agents (including other anti-dengue antibodies), vaccines (including dengue virus vaccines), or agents that enhance an immune response. In other embodiments, the antibody molécules are administered in combination with other therapeutic treatment modalities, such as intravenous hydration, fever-reducing agents (such as acetaminophen), or blood transfusion. Such combination thérapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies.
Examples:
Example 1: Upstream process for cell culturing and expression of therapeutic protein i.e. Dengue (VIS513) Monoclonal antibody
Protocol:
Cell culturing at 10 L scale was carried out in a Fed batch manner using below mentioned parameters during fermentation/upstream process.
The Dengue monoclonal antibody was expressed in cell line “CHO - K1 SV GS-KO obtained from Visterra Inc. USA.
• Cell culture medium used for cell growth and expression of therapeutic protein i.e. Dengue monoclonal antibody was 1X Cellvento™ CHO-220 Liquid Medium.
• Feed solution A, Feed solution B, Feed solution C, Feed solution D selected from group comprising of Glucose, Cell Boost™ 5 Supplément (Hyclone), EX-CELL 293 (Sigma Aldrich), Cell Boost 7a and 7b suppléments (Hyclone), 3X Actipro (Hyclone), Cell Vento 220 (3X medium), EX-CELL® Advanced™ CHO Feed 1 was used for supplémentation feed.
• pH of the fermentation medium was maintained at 6.7 to 7.5.
• Osmolality of the fermentation medium was maintained at <490 mOsm/Kg.
• Dissolved oxygen of the fermentation medium was maintained at about 20% to about 40%.
· Température of the fermentation medium was maintained at 36.5 ± 0.5.
• The culture was harvested upon drop in cell count to 60%
Feed supplémentation was done in a graduai drip manner as per following Table 1:
Table 1
Feeding Strategy protocol Day | Feed A | Feed B | Feed C | Feed D | Basal Medium 1 (3X Actipro” (Hyclone) | Basal Medium 2 (Cellvento™ CHO-220 (3X)) |
0 | ||||||
1 | ||||||
2 | 4% | |||||
3 | 10% | |||||
4 | 0.2% | 4% | 0.4% | |||
5 | 6% | 4% | 0.4% | |||
6 | 0.2% | 4% | 4% | 0.4% | ||
7 | 6% | 8% | ||||
8 | 0.2% | 4% | 0.4% | |||
9 | 4% | 4% | 4.0% | |||
10 | 0.1% | 2% | 4% | 0.4% | ||
11 | 0.2% | 2% | 2% | 0.2% | ||
12 | 4% | |||||
13 | 0.1% | 2% | 2% | 0.2% | ||
14 | 3% | |||||
15 | 3% | |||||
16 | __ |
Viable colony count and Yield obtained during the fermentation process was as follows:
Results & conclusion:
Table 2 : Viable colony count and Yield obtained during the fermentation process
Day | Batch 1 | Batch 2 | |||
Viable colony count | Titer gm/L | Viable colony count | Titer gm/L | ||
0 | 0.8 | 0.81 | |||
1 | 1.5 | 1.7 | |||
2 | 2.8 | 3.45 | |||
3 | 4.3 | 5.9 | |||
4 | 6.5 | 7.4 | |||
5 | 8.4 | 11.8 | |||
6 | 10.1 | 0.54 | 15.5 | 0.63 | |
7 | 12.7 | 0.77 | 18.5 | 0.91 | |
8 | 14.5 | 1.18 | 19 | 1.29 | |
9 | 17 | 1.62 | 18.5 | 1.76 | |
10 | 17.25 | 2.15 | 18.8 | 2.42 | |
11 | 17.25 | 2.64 | 18 | 2.85 | |
12 | 16.8 | 3.05 | 18 | 3.39 | |
13 | 15.3 | 3.6 | 17.2 | 4.0 | |
14 | 15 | 3.99 | 17 | 4.32 | |
15 | 14.7 | 4.43 | 14.9 | 4.68 | |
16 | 14.5 | 4.56 | 13.5 | 4.86 |
Applicant has found that by using Cell culture process comprising of basal medium, concentrated basal medium as feed solution, use of feed solutions along-with a definite feeding strategy, enhanced cell growth, lower concentrations of lactate and ammonia can be obtained thereby effectively maintaming the cell count and increasing cell longevity and high yield.Yield of greater than 4 gm/L was obtained in 10 fermentation process. Harvest obtained was further subjected to purification / downstream processing.
Example 2:
Cell culture obtained in example 1 was harvested and later subjected to protocol for purification of the dengue (VIS513) monoclonal antibody as per Figure 1
Detailed process used was as follows:
Protein-A Affinity Chromatography:
In this step targeted monoclonal antibody was separated from the media components in the harvested supernatant. Clarified supernatant was passed through the chromatography column and then eluted using compatible elution buffers.
Materials used:
Resin (Matrix): Mab Select Sure/Eshmuno A (Protein-A Affinity)
Résidence Time: 4.0-8.0 minutes
Column used: XK 26
Equilibration Buffer: 20 mM Phosphate Buffer + 150 mM NaCl + 0.05 %( w/v) Polysorbate 80, pH 7.0±0.2.
Wash I Buffer: 20 mM Phosphate Buffer + 150mM NaCl + 0.05% (w/v) Polysorbate 80, pH 7.0±0.2.
Wash II Buffer: 20 mM Phosphate Buffer + 1M NaCl + 0.05% (w/v) Polysorbate 80, pH 7.0±0.2.
Wash III Buffer: 10 mM Phosphate Buffer + 125 mM NaCl + 0.025% (w/v) Polysorbate 80, pH 6.0±0.2.
Elution Buffer: 20 mM Citrate buffer + 0.025% (w/v) Polysorbate 80, pH 3.0±0.2.
CIP Buffer : 0.1 M NaOH
Process Parameters used:
Table 3:
S. No. | Process Step | Column Volume | Linear Flow Rate (cm/hr) |
1 | Equilibration | 5 | <300 |
2 | Loading (mL) | As Actual | <300 |
3 | Wash I | 2 | <300 |
4 | Wash II | 4 | <300 |
5 | Wash III | 4 | <300 |
6 | Elution | 5 | <300 |
7 | Cleaning | 3 | <300 |
8 | Storage | 2 | <300 |
1. Low pH Viral inactivation
1. Eluate from protein-A Affinity chromatography was subjected to low pH i.e. 3.5±0.1 for 60±10 minutes to inactivate the viral particles.
ii. After low pH hold, eluate was neutralized using neutralization buffer i.e. 1 M Tris/Citrate buffer having pH 7.0±0.2.
iii. Conductivity of neutralized eluate was adjusted using WFI with 0.025% (w/v) Polysorbate 80.
2. Cation Exchange Chromatography
Positively charged antibody molécules bound with the column while negatively charged molécules corne in the flow through. Column bound antibody molécules are eluted using sait gradient.
Materials used:
Resin used: Fractogel SO3 / Fractogel SE Hicap (Merck)
Résidence Time : 4.00-7.00 minutes
Column used : XK 26
Pre Equilibration: 200 mM Citrate buffer pH 6.0±0.2.
Equilibration: 10 mM Citrate buffer +0.025% (w/v) Polysorbate 80, pH 6.0±0.2.
Loading: Low pH Hold neutralized.
Wash Buffer A: 10 mM Citrate buffer, pH 6.0±0.2.
Wash Buffer B: 20 mM Citrate buffer + 300 mM NaCI, pH 6.0±0.2.
CIP Buffer: 0.5 M NaOH
Storage Buffer: 0.1 M NaOH
Process Parameters:
Table 4:
S. No. | Process Step | CV | Linear Flow Rate (cm/hr) |
1 | Pre Equilibration | 2 | <300 |
2 | Equilibration | 5 | <300 |
3 | Loading | As Actual | <300 |
4 | Wash | 5 | <300 |
5 | Elution 0-60% B (Gradient) | 15 | <300 |
6 | 100 % B | 2 | <300 |
7 | CIP | 3 | <300 |
Fraction collection during gradient
Table 5:
S.No. | Fraction Name | Collection Criteria (UV280) mAU |
1 | Fraction 01 | Upto 300 |
2 | Fraction 02 | 300 - 700 |
3 | Fraction 03 | 700 till base line |
4 | Fraction 04 (100% B) | Baseline to base line |
Anion Exchange Chromatography:
Ail negatively charged impurities are bound with the membrane while antibody cornes in the flow through.
Materials used:
Membrane/Resin used: Sartobind Q single Sep mini (Sartorius)/Eshmuno Q
Loading volume: 150mg/mL-1000 mg/mL
Column used: XK 26
Cleaning Buffer: 0.5 M NaOH
Pre-equilibration buffer: 200 mM Citrate buffer, pH 6.0 ±0.2.
Equilibration Buffer: 20 mM Citrate buffer pH 6.0±0.2 ; and optionally 0.025% PS-80 pH 6.0±0.2
Storage Buffer: 0.1 M NaOH
Process Parameters:
Table 6:
S.No. | Process Step | Column Volume (CV) | Linear Flow Rate (cm/hr) |
1 | Cleaning | 10 | <300 |
2 | Pre Equilibration | 10 | <300 |
3 | Equilibration | 20 | <300 |
4 | Loading | As Actual | <300 |
5 | Post Load Wash | 20 | <300 |
6 | Cleaning | 10 | <300 |
3. Nano-filtration:
nm nanofilter i.e. Viresolve PRO (Merck), was used to remove any virus particles available in the therapeutic protein.
4. Tangential flow filtration / Ultra flow filtration:
The antibody was concentrated to desired concentration and buffer exchanged in one of the three formulation buffers.
Material used:
Formulation Buffer:
• Buffer 1: 25 mM Histidine buffer + 75 mM Arginine Buffer + 75 mM NaCI , pH 6.50 ±
0.25;
• Buffer 2: 25mM Histidine, 75mM Arginine, 101mM NaCI;
• Bufffer 3: 25mM Histidine, 75mM Arginine, 75mM to 101mM NaCI, Polysorbate-80
0.002 % w/v • Cleaning Buffer: 0.5 M NaOH
Storage Buffer: 0.1 M NaOH
Membrane used: PALL Centramate T Sériés, PES membrane MWCO: 30 kDa
Process Parameters:
Table 7
S. No. | Process Step | Description | Remark |
1 | Cleaning | 0.5 M NaOH | 30 Minutes recirculation 5 |
2 | WFI Cleaning | WFI, till conductivity cornes below 1.3 pS/cm | |
3 | Equilibration | 400 ml | - |
4 | Concentration and Diafiltration | ~ 10-12 DV pass | - |
5 | WFI | WFI wash 1000 mL | 10 |
6 | Cleaning | 0.5 M NaOH | 30 Minutes recirculation |
Stérile filtration
Stabilizer was added to the antibody solution and stérile filtered through 0.2 μ filter.
Results:
Stage wise recovery of the various steps used in the purification process.
Table 8:
S.No. | Stage | Recovery (%) | Purity (%) |
1 | Protein-A Affinity Chromatography | 98 | 99.3 |
2 | Low pH Viral Inactivation | 98 | |
3 | Cation Exchange Chromatography | 90 | 99.52 |
4 | Anion Exchange Chromatography | 95 | 99.46 |
5 | Nanofiltration | 100 | - |
6 | TFF/UFF | 98 | - |
7 | Formulation and Stérile filtration | 100 | - |
The overall process recovery was found to be ~ 80% and overall purity was found to be >99%.
Table 9: Impurity data
Assay | Accepted Criterion | Batch 1 | Batch 2 |
Purity by HP-SEC (% monomer) | Monomer should be >90.00%. Rétention time of monomer should be comparable to reference standard | 99.74 | 99.11 |
Residual CHO DNA (pg/mg of mAb) | <2 pg/mg IgG | 0.005 | 0.004 |
Residual Protein A (ng/mg of mAb) | < 10.00 ng/mg IgG | 1.05 | 0.82 |
Residual CHO Protein (ng/mg of mAb) | < 100.00 ng/mg IgG | 1.74 | 3.80 |
Endotoxin (EU/mg of protein) | < 0.1 EU/mg of protein | <0.05 | <0.05 |
Table 10 : Batch wise Recovery & Purity
S.No. | Batch No. | Recovery (%) | Purity (%) |
1 | Batch 1 | 85 | 99.21 |
2 | Batch 2 | 87 | 99.26 |
Example 3:
Purified Dengue (VIS513) monoclonal antibody was formulated as follows:
Excipients i.e. Arginine, Histidine, NaCI, Sucrose, and polysorbate-80 were added and mixed thoroughly using a magnetic stirrer at 50-60 RPM to form a mixture of excipients. This mixture was then added into the Dengue mAb TFF harvest gradually with stirring rate 50-60 RPM. pH was checked (pH 6.5) and if required adjusted by histidine-arginine buffer. The final formulation was filtered through a 0.2μΜ filter and filled into final container.
The concentration of each component in the final formulation was as follows:
Table 11:
Ingrédient | Formulation 1 | Formulation 2 | Formulation 3 |
Dengue Mab (VIS513) | 10 mg/ml | 25 mg/ml | 50 mg/ml |
Histidine | 25 mM | 25 mM | 25 mM |
Arginine | 75 mM | 75 mM | 75 mM |
Sodium Chloride | 101mM | 101mM | 101mM |
Sucrose | 0.5 % w/v | 0.5 % w/v | 0.5 % w/v |
Polysorbate-80 | 0.02% w/v | 0.02% w/v | 0.02% w/v |
pH | 6.510.5 | 6.510.5 | 6.510.5 |
Osmolality | 380 mOsm/kg | 380 mOsm/kg | 380 mOsm/kg |
These formulations were further tested for purity, stability, efficacy and potency for 9 months.
Example 4:
Effect of presence of Sucrose in VIS513 Dengue antibody formulation was studied for testing potency by ELISA assay on EDIII protein of DV1. The formulation studies were done for temp. 2 - 8 °C, 25 °C, and 40°C.
Results :
1. VIS513 Dengue antibody formulation without Sucrose
Table 12:
Ingrédient (QTY) | % Potency compared to Reference Standard Stored at 2-8°C | |||
2-8°C | RT (25°C) | 40°C | ||
15 Days | 30 Days | 15 Days | 30 Days | |
L- Histidine 25mM | 78.8 | 73.2 | 79.8 | 53.8 |
L- Arginine 75mM | ||||
Sodium chloride 75mM | ||||
Polysorbate 80 0.02% w/v |
2. VIS513 Dengue antibody formulation with Sucrose
Table 13:
Ingrédient (QTY) | % Potency compared to Reference Standard Stored at 2-8°C | |||
2-8°C | RT (25°C) | 40°C | ||
15 Days | 30 Days | 15 Days | 30 Days | |
L- Histidine 25mM | 90.5 | 86.3 | 94.6 | 81.6 |
L- Arginine 75mM | ||||
Sodium chloride 101mM | ||||
Polysorbate 80 0.02% w/v | ||||
Sucrose 0.5% w/v |
Reference Standard Formulation composition:
Ingrédient | (QTY) |
L- Histidine | 25mM |
L- Arginine | 75mM |
Sodium chloride | 101mM |
Polysorbate 80 | 0.02% w/v |
Sucrose | 0.5 % w/v |
Conclusion: Addition of 0.5% w/v improves stability as compared to the corresponding sampling point without sucrose.
Example 5:
VIS513 antibody formulation was stored at 40°C for 20 days and later potency of VIS513 was evaluated by ELISA test. Effect of increasing Sucrose Strength was studied on VIS513 10 antibody formulation at 40°C, wherein sucrose concentration of 0.1, 0.2 and 0.5% was evaluated.
Results:
Table 14:
Ingrédient (QTY) | % Potency compared to Reference Standard stored at 2-8°C |
L- Histidine 25mM | 53.8 |
L- Arginine 75mM | |
Sodium chloride 101mM | |
Polysorbate 80 0.02% w/v |
Table 15:
Ingrédient (QTY) | % Potency compared to Reference Standard stored at 2-8°C |
L- Histidine 25mM | 70.8 |
L- Arginine 75mM | |
Sodium chloride 101mM | |
Polysorbate 80 0.02% w/v | |
Sucrose 0.1% w/v |
Table 16:
Ingrédient (QTY) | % Potency compared to Reference Standard stored at 2-8°C |
L- Histidine 25mM | 65.7 |
L- Arginine 75mM | |
Sodium chloride 101mM | |
Polysorbate 80 0.02% w/v | |
Sucrose 0.2% w/v |
Table 17
Ingrédient (QTY) | % Potency compared to Reference Standard stored at 2-8°C |
L- Histidine 25mM | 81.6 |
L- Arginine 75mM | |
Sodium chloride 101mM | |
Polysorbate 80 0.02% w/v | |
Sucrose 0.5% w/v |
Reference Standard Formulation composition:
Ingrédient | (QTY) |
L- Histidine | 25mM |
L- Arginine | 75mM |
Sodium chloride | 101mM |
Polysorbate 80 | 0.02% w/v |
Sucrose | 0.5 % w/v |
Conclusion: Highest stability was observed formulation comprising 0.5% Sucrose.
Example 6:
Analytical test for purity, stability, efficacy and potency of Dengue (VIS513) Mab formulation with storage at • 2-8 °C for a period of 0 months, 3 months, 6 months, 9 months, 12 months and 18 months.
• 25 °C for a period of 0 days and 30 days • 40 °C for a period of 0 days, 7 days, 14 days, 28 days, 35 days, and 42 days.
6.1 : Potency of VIS513 antibody formulation was tested by indirect ELISA.
The indirect ELISA based method was used to quantify binding of Dengue Mab (VIS513) to EDIII protein of DV1 antigen. EDIII protein was immobilized to the plate. Unbound antigen was removed by washing. In the next, step standard and test samples were added, allowed to bind to the antigen. To détermine the amount of bound Dv-Mab, Mouse anti-Human IgG Fc-HRP, spécifie to Dv-Mab (human Immunoglobulin Fc fragment), was used to recognize the presence of Dv-Mab. The assay was developed with TMB Microwell Peroxidase Substrate System which quantifies the extent of binding by amount of color formed at 450 nm. The data analysis software generated a binding curve for each sample using a four parameter curve fitting model, and compared the binding curve of the test sample to the standard curve by calculating Relative Potency. The potency of a test sample is reported as % Activity relative to reference standard (Relative Potency times 100).
Results:
Table 18: Dengue (VIS513) Mab potency ( %) by indirect ELISA for formulation stored at 2 - 8 °C.
0 day | 3 months | 6 months | 9 months | 12 months | 18 months | |
Batch 1 | 74.90 | 79.30 | 89.30 | 84.9 | 88.50 | 93.90 |
Batch 2 | 74.30 | 80.05 | 82.20 | 86.7 | 79.00 | 94.70 |
Batch 3 | 91 | 98.30 | 125 | 99.70 | 88.80 | 118.40 |
Batch 4 | 97.5 | 102.2 | 92.6 | 84 | 83.80 | 96.70 |
Table 19: Dengue (VIS513) Mab potency (%) by indirect ELISA for formulation stored at °C.
0 day | 30 days | |
Batch 1 | 74.90 | 79.30 |
Batch 2 | 74.30 | 87.8 |
Table 20: Dengue (VIS513) Mab potency (%) by indirect ELISA for formulation stored at °C.
0 day | 14 days | 21 days | 28days | 35 days | 42 days | |
Batch 1 | 70.3 | 82.80 | 96.20 | 71.90 | 89.70 | 90.80 |
Dengue (VIS513) mab formulation did not show any time dépendent loss of binding affinity.
6.2 : PRNT assay to détermine EC50
The assay involves premixing serially diluted antibody with virus to allow antibody 15 binding,-neutralization then transfer of mixture to a Vero cell monolayer, overlay with a viscous medium, incubation (~3-7 days, depending on virus serotype) to allow limited virus réplication and spread, followed by détection of plaques. Neutralization was captured by the réduction of plaque formation. Robust détection was achieved with immunostaining methods, using mouse 4G2 Anti-Dengue antibody and HRP-labelled goat anti-mouse antibody with Peroxidase substrate.
The Dengue (VIS513) Mab formulation samples were been tested against ail four serotypes of dengue viruses i.e. DV1, DV2, DV3 and DV4. EC50 value was calculated for 5 neutralization of Dengue viruses. EC50 value représente the 50% effective concentration required for the effective neutralization of dengue viruses and EC50 value calculated from number of plaques présent in the virus control wells and number of plaques in the wells in which mab-Virus incubated samples were added.
Results:
Table 21: Dengue (VIS513) mAb EC50 (ng/ml) value by PRNT assay for formulation stored at 2 - 8 °C.
Batch # | Dengue virus sero types | 0 day | 3 months | 6 months | 9 months | 12 months | 18 months |
Batch 1 | DV1 | 47.15 | 49.74 | 23.88 | 24.12 | Not Done | 42.58 |
DV2 | 5.9 | 8.03 | 3.58 | 3.31 | Not Done | 13.03 | |
DV3 | 14.38 | 14.7111 | 5.58 | 4.57 | Not Done | 18.14 | |
DV4 | 30.29 | 50.75 | 23.96 | 23.35 | Not Done | 117597 | |
Batch 2 | DV-1 | 21.03 | 21.01 | 16.12 | 29.41 | Not Done | 62.94 |
DV-2 | 3.26 | 5.69 | 4.15 | 2.87 | Not Done | 8.59 | |
DV-3 | 13.19 | 24.14 | 6.53 | 7.05 | Not Done | 27.83 | |
DV-4 | 22.46 | 22.44 | 16.61 | 19.56 | Not Done | 155207 | |
Batch 3 | DV-1 | 32.77 | 13.74 | 27.76 | 34.22 | Not Done | 60.48 |
DV-2 | 4.34 | 7.37 | 2.94 | 4.26 | Not Done | 16.8 | |
DV-3 | 15.43 | 4.96 | 6.76 | 7.74 | Not Done | 14.21 | |
DV-4 | 30.49 | 16.36 | 39.71 | 31.75 | Not Done | 141205 | |
Batch 4 | DV-1 | 22.81 | 24.67 | 23.34 | 46.72 | Not Done | 23.48 |
DV-2 | 3.16 | 3.25 | 1.25 | 6.35 | Not Done | 23.49 | |
DV-3 | 11.42 | 7.35 | 4.65 | 5.34 | Not Done | 128.6 | |
DV-4 | 21.39 | 24.58 | 19.56 | 22.31 | Not | Done | 15814 |
Table 22: Dengue (VIS513) Mab EC50 (ng/ml) value by PRNT assay for formulation stored at 25 °C.
Batch # | Dengue virus serotypes | 0 day | 30 days |
Batch 1 | DV1 | 47.15 | 29.82 |
DV2 | 5.9 | 5.6 | |
DV3 | 14.38 | 9.63 | |
DV4 | 30.29 | 35.28 | |
Batch 2 | DV1 | 21.03 | 28.34 |
DV2 | 3.26 | 5.51 | |
DV3 | 13.19 | 9.25 | |
DV4 | 22.46 | 30.69 |
Table 23: Dengue (VIS513) Mab EC50 (ng/ml) value by PRNT assay for formulation stored at 40 °C.
Batch # | Dengue virus DV2 serotypes | Control | Test |
Batch 1 | 0 day | 6.66 | - |
7 days | 6.37 | 26.89 | |
14 days | 6.18 | 36.12 |
Dengue (VIS513) mab formulation did not show any time dépendent loss of virus neutralization efficacy at 2-8°C & 25°C. VIS513 formulation even if kept at 40°C,does not lose its ability to neutralize dengue virus.
6.3 : Aggregation and purity analysis
A HPLC- based size exclusion chromatography (HPLC-SEC) was used to assess the aggregates in the bulk and final formulation of DV Mab. In this method a phenomenex BioSec-S 3000 column was used to demonstrate the aggregates and monomer percentage of Dengue (VIS513) Mab by injecting the ~50 ug of total antibody and run at a flow rate of 1 ml/minute for 35 minutes. Phosphate buffered Saline (PBS), pH 6.5 was used as mobile phase.
Results: SEC-HPLC (Acceptance range is NLT 90%)
Table 24: SEC-HPLC analysis of formulation stored at 2 - 8 °C
Batch | 0 Day | 3 months | 6 months | 9 month | 12 month | 18 month | |
1 | % Monomers | 99.21 | 98.60 | 99.14 | 98.55 | 98.25 | 98.14 |
% Aggregate | 0.78 | 1.39 | 0.85 | 1.44 | 1.74 | 1.85 | |
2 | % Monomers | 99.26 | 98.81 | 98.89 | 98.53 | 98.36 | 98.18 |
% Aggregate | 0.73 | 1.18 | 0.86 | 1.45 | 1.63 | 1.81 | |
3 | % Monomers | 99.25 | 99.35 | 98.99 | 98.81 | 98.78 | 98.22 |
% Aggregate | 0.74 | 0.64 | 1.00 | 1.18 | 1.18 | 1.77 | |
4 | % Monomers | 99.25 | 99.12 | 98.69 | 98.93 | 98.42 | 93.48 |
% Aggregate | 0.74 | 0.82 | 1.30 | 1.06 | 1.42 | 1.95 |
Protein Concentration Analysis
Table 24A: Protein Concentration (mg/ml) Analysis by UV measurement of formulation stored at 2 - 8°C
Batch | 0 Day | 3M | 6M | 9M | 12M | 18M |
1 | 25.94 | 25.24 | 25.13 | 24.71 | 25.37 | 22.71 |
2 | 25.80 | 25.20 | 25.75 | 24.59 | 26.63 | 23.72 |
3 | 24.72 | 24.39 | 24.75 | 25.67 | 24.02 | 24.79 |
4 | 26.04 | 26.23 | 26. 27 | 26.92 | 26.63 | 25.4 |
Sub-Visible Particle Analysis of formulation stored at 2 - 8 °C
Particulate matter in injections consists of mobile undissolved particles, other than gas bubbles, unintentionally présent in the solutions. Particulate matter in Dengue (VIS513) mAb formulated bulk was analyzed over period of time. For parenterals with less than 100 ml volume, the test passes when per container less than 6000 particles of size equal or greater than 10 μ or less than 600 particles of size equal or greater than 25 μ are observed.
Table 24B:
Particle Size | fime Point (No. of particles/ml) | |||
Initial | 3M | 6M | 12M | |
>10 μ | 1 | 3 | 5 | 9 |
>25 μ | 0 | 0 | 3 | 1 |
The formulated bulk shows stability as only marginal increase in particulate matter was observed.
Table 25: SEC-HPLC analysis of formulation stored at 25 °C
0 day | 30 days | |
Batch 1 | 99.21 | 97.63 |
Batch 2 | 99.26 | 97.58 |
Table 26: SEC-HPLC analysis of formulation stored at 40 °C
0 day | 7 days | 14 days | 21 days | 28days | 35 days | 42 days | |
Batch 1 | 99.21 | 99.30 | 99.50 | 97.74 | 97.30 | 98.70 | 95.30 |
Dengue (VIS513) mab formulation did not show any significant time dépendent aggregation; and purity/ monomer content was found to be >98%.
Protein Concentration Analysis
Table 26A: Protein Concentration (mg/ml) Analysis by UV measurement of formulation stored at 40°C
Batch | 0 Day | 3 day | 7 day | 15 day |
1 | 27.53 | 26.09 | 25.46 | 26.58 |
The variation in protein concentration measurement was found to be within variability of test analysis by UV measurement.
pH and Identification (Isoelctrofocusinq) Studies on Dengue (VIS513) mAb formulation stored at 40 deq C,
Table 26B: pH measurement of Dengue (VIS513) mAb formulation stored at 40 °C
Batch | 0 Day | 3 day | 7 day | 15 day |
1 | 6.4 | 6.38 | 6.38 | 6.33 |
Table 26C: Identification by SDS PAGE (Reducing /nonreducing) & Isoelectrofocusing of Dengue (VIS513) mAb formulation stored at 40 °C
Test | 0 Day | 3 day | 7 day | 15 day |
SDS PAGE (Reducing) | Single diffused band corresponding in position and intensity with | NA | NA | Single diffused band corresponding in position and intensity with |
SDS PAGE (NonReducing) | Single diffused band corresponding in position and intensity with reference standard | NA | NA | Single diffused band corresponding in position and intensity with reference standard |
Isoelectrofocusing Std pl= 7.8±0.3 | Comparable with the internai reference standard pl | NA | NA | Comparable with the internai reference standard pl______ |
Example 7:
Effect of surfactant concentrations of Formulations:
Effect of Surfactant concentration was evaluated by sub-visible particle analysis. Formulations varying Polysorbate-80 strengths were prepared and analyzed for Sub visible particle analysis.
Table 27
----------------------------------------------------------' | Formulation with Polysorbate 80 conc (% W/V) ____ | ||
0.0016 % | 0.002% | 0.005% | |
Particle size | |||
S2p | 916 | 211 | 20 |
>5μ | 55 | 48 | 5 |
> 10 μ | 6 | 16 | 2 |
>25 μ | 1 | 1 | 0 |
Conclusion:
In the formulation containing 0.005% w/v Polysorbate-80 minimum sub visible particles were observed. Depending on dose, if the formulation requires dilution Polysorbate 80 strength was finalized 0.02% w/V with margin of 4 fold.
Example 8: Study of détermination of minimum concentration of stabilizers used
Minimum buffer strength required (10-30mM) was referred from the available literature. To find out minimum Arginine (used as solubilising agent and viscosity reducing agent) Mab sample was buffer exchanged into normal saline and Arginine stock solution (300mM) was gradually added. The aggregation of the solution was monitored by measuring OD@350nm. The saline 10 with 75mM Arginine gave lowest OD hence 75mM Arginine was finalized.
Example 8
Viscosity studies of Dengue (VIS513) antibody formulation
Viscosity of DV mab samples was measured on a microchip based Viscometer, Model: microVISCTM (Make: RheoSense, CA USA) as per procedure mentioned in the instrument 15 manual.
Table 28
Sample | Measurement Température | Viscosity mPa-S |
Day 0 | 5°C | 2.04 |
25°C | 1.164 | |
Day 90 stored at 2-8°C | 25°C | 1.173 |
Day 180 stored at 2-8°C | 25°C | 1.167 |
Day 180 stored at 2-8°C | 25°C | 1.166 |
Day 180 stored at 2-8°C | 25°C | 1.174 |
Day 365 stored at 2-8°C | 25°C | 1.175 |
Day 30 stored at 25°C | 25°C | 1.137 |
Day 60 stored at 25°C | 25°C | 1.127 |
Day 90 stored at 25°C | 25°C | 1.122 |
Conclusion:
No time dépendent increase in viscosity was observed in the mab formulation stored at 2-8°C for 90 days as well at a sample kept at 25°C for 1 month, this is primarily due to the excipientArginine 75mM.Viscosity of our formulation was found to be 1.1 to 1.2 mPa-S /cP, which is lower than other marketed formulations that hâve viscosity between 11-50 mPa-S /cP. Viscosity of the bulk sample does not increase even after storage for 1 year at 2-8 deg C or storage for 3 months at 25 deg C.
Example 9: Viral Spiking Studies on Dengue (VIS513) mAb purification process
Virus validation was performed for actual manufacturing process, to test the effectiveness of the virus removal by virus filtration in the manufacturing process of monoclonal antibody.
Murine Leukemia Virus (MuLV) and Minute virus of mice (MMV/MVM) were used as model organisms. Inventors of this invention compared the ability of their inventive purification process with that of the general and well established method of monoclonal antibody purification.
The general and well established method of monoclonal antibody purification comprised of Protein-A Affinity Chromatography (GE Resin); Low pH Treatment; Sartobind Q Chromatography (Anion Exchange Membrane, Sartorius, single use); Sartobind Phenyl Chromatography (Membrane Chromatography, Sartorius, single use); Viresolve Pro filtration (Nanofiltration, Merck).
Table 29: | Logio Viral Réduction Factor (LRV) | ||
MuLV | MMV | ||
A | General /Standard method | >12.64 ± 0.60 | 7.02 ± 0.69 |
B | Inventive method (SIIPL) | >18.3 ± 0.60 | 14.72 ±0.70 |
Table 29A, Details of Method used in Row A of table 29:
General /Standard Dengue Monbclonal Antibody Purification Process | ||
Step | Logio Viral Réduction Factor | |
MuLV | MMV | |
Protein-A Affinity Chromatography (GE Resin) | 2.75 ± 0.10 | 1.52 ± 0.46 |
Low pH Treatment | 2.89 ± 0.28 | Not applicable* |
Sartobind Q Chromatography (Anion Exchange Membrane, Sartorius, single use) | 1.15 ± 0.43 | 2.19 ± 0.44 |
Sartobind Phenyl Chromatography (Membrane Chromatography, Sartorius, single use) | 2.09 ±0.17 | Not tested |
Viresolve Pro filtration (Nanofiltration, Merck) | >3.76 ±0.25 | 3.31 ± 0.26 |
Cumulative Log 10 Réduction Factor | >12.64 ±0.60 | 7.02 ±0.69 |
Table 29B, Details of Method used in Row B of table 29:
SIIPL’s Inventive Dengue Monoclonal Antibody Purification Process (SIIPL) | ||
Step | Logw Viral Réduction Factor | |
MuLV | MMV | |
Protein-A Affinity Chromatography (Merck) | 2.27 ± 0.17 | 2.35 ± 0.45 |
Low pH Treatment | 4.14 ±0.26# | Not applicable* |
Cation Exchange Chromatography (Merck) | 2.31 ± 0.31 | 2.73 ± 0.44 |
Anion Exchange Chromatography (Merck) | 4.38 ±0.36 | 2.96 ± 0.44 |
Viresolve Pro filtration (Nanofiltration, Merck) | >5.20 ± 0.28 | 6.68 ±0.90 |
Cumulative Log 10 Réduction Factor | 18.3 ±0.60 | 14.72 ± 0.70 |
NOTE: *MMV is non-envelope virus and highly résistant at acidic pH. So low pH treatment stage is not evaluated.
Calculation of Retrovirus particles per dose in accordance with the general method and SIIPL method
As per ICH Q5A, less than one particle per million doses is expected.
Table 29C: Comparision of the two methods as per Row A and Row B or Table 29
Description | General /Standard method | Inventive method (SIIPL) |
Maximum Load of RVLPs/mL in unprocessed bulk determined by électron microscopy (Visterra Data) | 8.5x106 (A) | 8.5x106 (A)$ |
Total Volume of Unprocessed bulk entering in purification Process (L) | 770.85 (B) | 300 (B) |
Product Yield for Batch (g) | 720.32 (C ) | 625 (C) |
Maximum single dose proposed 75mg/kg (Visterra),25mg/kg (SIIPL) average patient 80 KG | 6(D) | 2* (D) |
Volume of unprocessed bulk required to make single dose of product (L) | 6.42089 (D) -{C/B} | 0.960 (D) -{C/B} |
Volume of unprocessed bulk required to make single dose of product (mL) | 6420.89 (E) | 960.0 (E) |
Virus réduction factor determined by spiking study | >12.64log10 | 18.3 Iog10 |
Antilog of réduction factor | >4.37X1012 (F) | 1.99X1018 (F) |
Estimated Virus particles per dose AXE | 8.5X106 X6420.89 4.37X1012 =1.25X10-2 (G) | 8.5X106 X961.5 1.99X1018 =4.1X10’9 (G) |
F | ||
Therefore would expect 1 virus like particle every (1/G) maximum doses | 8.0X101 doses | 2.4X108 |
Conclusion | 1 viral particle would be présent in 80 doses of the product. | 1 viral particle would be présent in 240 million doses of the product |
Results:
SIIPL inventive purification process is highly efficient in viral clearance, total LRV (MuLV) achieved was 18.3 i.e at least 18 logio,réduction factor while with General /Standard method it was 12.64; total LRV (MMV) achieved was at least 14 logw,réduction factor, while with General /Standard method it was 7.02.
• One viral particle would be présent in 240 million doses of the product using SIIPL inventive purification process (dose of 2.0 gram).
• One viral particle would be présent in 80 doses of the product using General /Standard method purification process.
Dengue monoclonal antibody purified using SIIPL inventive purification process can be used for human clinical trials without any viral risk
SIIPL purification process was highly efficient in viral clearance, total LRV achieved is as per the ICH guidelines. (Standard Process LRV 12.64 while SIIPL inventive process 18.3) Dengue antibody purified using our inventive process was found to be suitable for human clinical trials without any viral risk.
Example 10: Upstream process for cell culturing and expression of therapeutic protein i.e. Rabies Monoclonal antibody
Protocol:
Cell culturing at 2 L scale was carried out in a Fed batch manner using below mentioned parameters during fermentation/upstream process.
• The rabies monoclonal antibody was expressed in cell line “GS - CHO”.
• Cell culture medium used for cell growth and expression of therapeutic protein i.e. Rabies monoclonal antibody was “1X Cellvento™ CHO-220 Liquid Medium” or “Actipro 1x (Hyclone)” • Feed solution A, Feed solution B, Feed solution C, Feed solution D selected from group comprising of Glucose, Cell Boost™ 5 Supplément (Hyclone), EX-CELL 293 (Sigma Aldrich), Cell Boost 7a and 7b suppléments (Hyclone), 3X Actipro (Hyclone), Cell Vento 220 (1X medium), EX-CELL® Advanced™ CHO Feed was used for supplémentation feed.
• pH of the fermentation medium was maintained at 6.5 to 7.5.
• Osmolality of the fermentation medium was maintained between 270 - 450 mOsm/Kg.
• Dissolved oxygen of the fermentation medium was maintained at about 20% to about 60%.
• Température of the fermentation medium was maintained at 36.5 ± 1.
Feed supplémentation was done in a graduai drip manner as per following table:
Table 30:
Day | Feed A | Feed B | Feed C | Feed D | Basal Medium 1 (3X Actipro” (Hyclone) | Basal Medium 2 (Cellvento™ CHO-220 (1X)) |
0 | ||||||
1 | ||||||
2 | 4% | |||||
3 | 0.2% | |||||
4 | 4% | 0.4% | 10% | 8% | ||
5 | 6% | 4% | 0.4% | |||
6 | 0.2% | 4% | 4% | 0.4% | ||
7 | 6% | |||||
8 | 0.2% | 4% | 0.4% | |||
9 | 4% | 4% | 4.0% | |||
10 | 0.1% | 2% | 4% | 0.4% | ||
11 | 0.2% | 2% | 2% | 0.2% | ||
12 | 4% | |||||
13 | 0.1% | 2% | 2% | 0.2% | ||
14 | 3% | |||||
15 | 3% | |||||
16 |
Note: AH feeding solutions may vary by ±1%and by ± 1 day.
The cell culture was harvested upon drop in OD upto 60%
Results & conclusion:
Yield of 3 - 5 gm/L was obtained of the fermentation process. Harvest obtained was further subjected to purification / downstream processing.
Example 11:
Cell culture obtained acôording to example 9 was harvested and later subjected to protocol for purification of the rabies monoclonal antibody as per Figure 1.
Detailed process used was as follows:
Protein-A Affinity Chromatography:
In this step targeted monoclonal antibody was separated from the media components in the harvested supernatant. Clarified supernatant was passed through the chromatography column and then eluted using compatible elution buffers.
Materials used:
Resin (Matrix): Mab Select Sure/Eshmuno A (Protein-A Affinity)
Résidence Time: 4.0-8.0 minutes
Column used: XK 26
Equilibration Buffer: 20 mM Phosphate Buffer +150 mM NaCI + 0.05 %( w/v) Polysorbate 80, pH 7.0±0.2.
Wash I Buffer: 20 mM Phosphate Buffer + 150mM NaCI + 0.05% (w/v) Polysorbate 80, pH 7.0±0.2.
Wash II Buffer: 20 mM Phosphate Buffer + 1M NaCI + 0.05% (w/v) Polysorbate 80, pH 7.0±0.2.
Wash III Buffer: 10 mM Phosphate Buffer + 125 mM NaCI + 0.025% (w/v) Polysorbate 80, pH 6.0±0.2.
Elution Buffer: 20 mM Citrate buffer + 0.025% (w/v) Polysorbate 80, pH 3.0±0.2.
CIP Buffer : 0.1 M NaOH
Process Parameters used:
Table 31
S. No. | Process Step | Column Volume | Linear Flow Rate (cm/hr) |
1 | Equilibration | 5 | <300 |
2 | Loading (mL) | As Actual | <300 |
3 | Wash I | 2 | <300 |
4 | Wash II | 4 | <300 |
5 | Wash III | 4 | <300 |
6 | Elution | 5 | <300 |
7 | Cleaning | 3 | <300 |
8 | Storage | 2 | <300 |
1. Low pH Viral inactivation
i. Eluate from protein-A Affinity chromatography was subjected to low pH i.e. 3.5±0.1 for 60±10 minutes to inactivate the viral particles.
ii. After low pH hold, eluate was neutralized using neutralization buffer i.e. 1 M Tris/Citrate buffer having pH 7.0±0.2. Subsequently neutralized solution was filtered using 0.8/0.45 μ or 0.8/0.2 μ.
iii. Conductivity of neutralized eluate was adjusted using WFI with 0.025% (w/v) Polysorbate 80.
2. Cation Exchange Chromatography
Positively charged antibody molécules bound with the column while negatively charged molécules corne in the flow through. Column bound antibody molécules are eluted using sait gradient.
Materials used:
Resin used: Fractogel SO3 / Fractogel SE Hicap (Merck)
Résidence Time : 4.00-7.00 minutes
Column used : XK 26
Pre Equilibration: 200 mM Citrate buffer pH 6.0±0.2.
Equilibration: 10 mM Citrate buffer +0.025% (w/v) Polysorbate 80, pH 6.0±0.2.
Loading: Low pH Hold neutralized.
Wash Buffer A: 10 mM Citrate buffer, pH 6.0±0.2.
Wash Buffer B: 20 mM Citrate buffer + 300 mM NaCI, pH 6.0±0.2.
CIP Buffer: 0.5 M NaOH
Storage Buffer: 20% éthanol + 150mM NaCI
Table 32: Process Parameters:
S. No. | Process Step | cv | Linear Flow Rate (cm/hr) |
1 | Pre Equilibration | 2 | <300 |
2 | Equilibration | 5 | <300 |
3 | Loading | As Actual | <300 |
4 | Wash | 5 | <300 |
5 | Elution 0-60% B (Gradient) | 15 | <300 |
6 | 100 % B | 2 | <300 |
7 | CIP | 3 | <300 |
Table 33: Fraction collection during gradient
S.No. | Fraction Name | Collection Criteria (UV2so) mAU |
1 | Fraction 01 | Upto 300 |
2 | Fraction 02 | 300 - 700 |
3 | Fraction 03 | 700 till base line |
4 | Fraction 04 (100% B) | Baseline to base line |
Anion Exchange Chromatography:
Ail negatively charged impurities are bound with the membrane while antibody cornes in the flow through.
Materials used:
Membrane/Resin used: Sartobind Q single Sep mini (Sartorius)/Eshmuno Q
Loading volume: 150mg/mL-1000 mg/mL
Column used: XK 26
Cleaning Buffer: 0.5 M NaOH
Pre-equilibration buffer: 200 mM Citrate buffer, pH 6.0 ±0.2.
Equilibration Buffer: 20 mM Citrate buffer pH 6.0 ± 0.2 ; and optionally 0.025% PS-80 pH 6.0±0.2
Storage Buffer: 20% éthanol +
150mM NaCI or 0.1 M NaOH
Table 34: Process Parameters:
S.No. | Process Step | Column Volume (CV) | Linear Flow Rate (cm/hr) |
1 | Cleaning | 10 | <300 |
2 | Pre Equilibration | 10 | <300 |
3 | Equilibration | 20 | <300 |
Loading | As Actual | <300 | |
Post Load Wash | 20 | <300 | |
6 | Cleaning | 10 | <300 |
-filtration:
nm nanofilter i.e. Viresolve PRO (Merck), was used to remove any virus particles available in the therapeutic protein.
4. Tangential flow filtration / Ultra flow filtration:
The antibody was concentrated to desired concentration and buffer exchanged in one of the three formulation buffers.
Material used:
Formulation Buffer:
• Buffer 1: 25 mM Histidine buffer + 75 mM Arginine Buffer + 75 mM NaCI , pH 6.50 ±
0.25;
• Buffer 2: 25mM Histidine, 75mM Arginine, 101mM NaCI;
• Bufffer 3: 25mM Histidine, 75mM Arginine, 75mM to 101mM NaCI, Polysorbate-80
0.002 % w/v • Cleaning Buffer: 0.5 M NaOH
Storage Buffer: 20% éthanol + 150mM NaCI or 0.1 M NaOH
Membrane used: PALL Centramate T Sériés, PES membrane MWCO: 30 kDa
Table 35 : Process Parameters:
S. No. | Process Step | Description | Remark |
1 | Cleaning | 0.5 M NaOH | 30 Minutes recirculation |
2 | WFI Cleaning | WFI, till conductivity | - |
cornes below 1.3 pS/cm | |||
3 | Equilibration | 400 ml | - |
4 | Concentration and Diafiltration | ~ 10-12 DV pass | - |
5 | WFI | WFI wash 1000 mL | 5 |
6 | Cleaning | 0.5 M NaOH | 30 Minutes recirculation |
Stérile filtration
Stabilizer was added to the antibody solution and stérile filtered through 0.2 μ filter.
Results:
Table 36: Stage wise recovery of the various steps used in the purification process.
S.No. | Stage | Recovery (%) * |
1 | Protein-A Affinity Chromatography | 94 |
2 | Low pH Viral Inactivation | 98 |
3 | Cation Exchange Chromatography | 94 |
4 | Anion Exchange Chromatography | 95 |
5 | Nanofiltration | 100 |
6 | TFF/UFF | 98 |
7 | Formulation and Stérile filtration | 100 |
The overall process recovery was found to be > 80%.
Table 37: Impurity data
Assay | Accepted Criterion | Batch 1 | Batch 2 |
Concentration by UV280 (mg/ml) | - | 26.19 | 24.39 |
Purity by SEC-HPLC (% monomer) | Monomer should be >90.00%. Rétention time of monomer should be comparable to | 100 | 100 |
reference standard | |||
SDS PAGE NR(kD) | - | 156.0 | 156.0 |
SDS PAGE R (kD) | 50.4/27.7 | 50.7/27.9 | |
Residual CHO DNA (pg/mg of mAb) | <2 pg/mg IgG | 0.34 | 0.17 |
Residual Protein A (ng/mg of mAb) | < 10.00 ng/mg IgG | <10 | <10 |
Residual CHO Protein (ng/mg of mAb) | < 100.00 ng/mg IgG | 5.50 | 7.94 |
Bacterial Endotoxin (EU/mg of protein) | < 0.1 EU/mg of protein | 0.35 | 0.5 |
Table 38: Batch wise Recovery & Purity
S.No. | Batch No. | Recovery (%) | Purity (%) |
1 | Batch 1 | 82 | 99.4 |
2 | Batch 2 | 80 | 99.6 |
The overall purity of the rabies mab after purification was found to be >99% and overall recovery was found to be >80%.
Example 12:
Purified Rabies monoclonal antibody was formulated as per the flowchart given in figure 2.
Excipients i.e. Arginine, Histidine, NaCI, Sucrose, and polysorbate-80 were added and mixed thoroughly using a magnetic stirrer at 50-60 RPM to form a mixture of excipients. This mixture 10 was then added into the Dengue mAb TFF harvest gradually with stirring rate 50-60 RPM. pH was checked (pH 6.5) and if required adjusted by histidine-arginine buffer. The final formulation was filtered through a 0.2μΜ filter and filled into final container.
The concentration of each component in the final formulation was as follows:
Table 39:
Ingrédient | Formulation 1 | Formulation 2 | Formulation 3 |
Rabies Mab | 10 mg/ml | 25 mg/ml | 50 mg/ml |
Histidine | 25 mM | 25 mM | 25 mM |
Arginine | 75 mM | 75 mM | 75 mM |
Sodium Chloride | 101mM | 101mM | 101mM |
Sucrose | 0.5 % w/v | 0.5 % w/v | 0.5 % w/v |
Polysorbate-80 | 0.02% w/v | 0.02% w/v | 0.02% w/v |
pH | 6.5+0.5 | 6.5+0.5 | 6.5+0.5 |
Osmolality | 386 mOsm/kg | 386 mOsm/kg | 386 mOsm/kg |
These formulations were further tested for purity, stability, efficacy and potency for 9 months.
Example 13: Analytical test for purity & stability of Rabies Mab formulation with storage at 2-8, 25 and 40 °C for a period of 0 months, 1 month, 3 months, & 6 months.
13.1 Aggregation and purity analysis
A HPLC- based size exclusion chromatography (HPLC-SEC) was used to assess the aggregates in the bulk and final formulation of DV Mab. In this method a phenomenex Bio-Sec-S 3000 column was used to demonstrate the aggregates and monomer percentage of Rabies Mab by injecting the ~50 ug of total antibody and run at a flow 10 rate of 1 ml/minute for 35 minutes. Phosphate buffered Saline (PBS), pH 6.5 was used as mobile phase.
Results:
Table 40: SE- HPLC (%) results
Temp. | 0 day | 1 months | 3 months | 6 months |
2-8 °C | 100 | 99.70 | 99.40 | 99.60 |
25 °C | 100 | 99.60 | - | - |
40 °C | 100 | 99.20 (7days) | - | - |
Rabies mab formulation did not show any time dépendent aggregation and purity/ monomer content was found to be >99%.
13.2 SDS Page Analysis Batch 1 - Test Sample at 2-8 °C
Table 41:
0 Day | 1M | 3M | 6M | |||
SDS PAGE REDUCING (kD) Molecular weight of heavy and light chains must be within ±10% of molecular weight of reference standard. Total % of heavy and light chain must be >95%. Total % : 100 | Test Sample at 2-8 °C | Heavy Chain | 50.8 | 49.8 | 49.3 | 49.2 |
Light Chain | 25.6 | 25.7 | 25.6 | 26.4 | ||
Reference standard | Heavy Chain | 50 | 50 | 50 | 50 | |
Light Chain | 25 | 25 | 25 | 25 |
SDS-PAGE Non-Reducing (kD) RS: Reference standard Molecular weight of major band must be within ± 10% of molecular weight of reference standard (RS). | Test Sample at 2-8 °C | 151.0 | 156.7 | 157.2 | 157.6 |
Reference standard | 150 | 150 | 150 | 150 |
Test sample at 25 °C
0 Day | 30 Days | |||
SDS PAGE REDUCING (kD) Molecular weight of heavy and light chains must be within ±10% of molecular weight of reference standard. Total % of heavy and light chain must be >95%. Total % : 100 | Test Sample at 25 °C | Heavy Chain | 50.8 | 47.5 |
Light Chain | 25.6 | 25.5 | ||
Reference standard | Heavy Chain | 50 | 50 | |
Light Chain | 25 | 25 | ||
SDS-PAGE Non-Reducing (kD) RS: Reference standard Molecular weight of major band must be within ± 10% of molecular weight of reference standard (RS). | Test Sample at 25 °C | 151.0 | 151.6 |
Reference standard | 150 | 150 |
Conclusion: Rabies mAb formulation did not show any significant time dépendent changes in aggregation and change in molecular weight. Hence the formulation is found to be stable at 2 8 °C 25 °C, AND 40 °C.
Seq ID 1: VH amino acid sequence ofVIS513 (Dengue Monoclonal Antibody)
QVQLVQSGAEVKKPGASVKVSCKAGFNIKDVYMSWVRQAPEQGLEWMGRIDPENGDTKYD 60
PKLQGRVTMTADTSTNTAYMELRSLRSDDTAVYYCARGWEGFAYWGQGTLVTVSSASTKG 120
PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL 180
SSWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFL 240
FPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV 300
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ 360
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV 420
FSCSVMHEALHNHYTQKSLSLSPGK 445
Seq ID 2: VL amino acid sequence of VIS513 (Dengue Monoclonal Antibody)
DIVMTQSPASLAVSLGERATISCRASENVDKYGNSFMHWYQQKPGQPPKLLIYRASELQW 60
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQRSNEVPWTFGQGTKLEIKRTVAAPSVF 120
IFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS 180
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 218
Seq ID 3: SU RmAb (RAB1)(17C7) Heavy Chain Amino Acid Sequence
QVQLVESGGGWQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAWSYDGRTKDY 60
ADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYFCARERFSGAYFDYWGQGTLVTVSSA 120
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG 180
LYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGP 240
SVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS 300
TYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM 360
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ 420
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 449
Seq ID 4: SU RMAb (RAB1)(17C7) Light Chain Amino Acid Sequence
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA 60
RFSGSGSGTDFTLTISSLEPEDFAVYSCQQRNNWPPTFGGGTKVEIKRTVAAPSVSVFIF 120
PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST 180
LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
Claims (89)
- We Claim1. The method of manufacturing pharmaceutical antigen binding protein with high yield and minimum aggregation, comprising:a) culturing in large scale mammalian cells that express antigen binding protein in a cell culture production medium, wherein the process effectively maintains the cell count and results in yield of atleast 2 gm/L;b) purification of antigen binding protein from harvested supernatant obtained in step (a), wherein the process results in recovery of atleast 80%, purity of atleast 99%;c) stable formulation, wherein Osmolality is in range of 300 - 400 mOsm/Kg and viscosity is less than 2.5 mPa-S.
- 2. The method of claim 1 comprising culturing in large scale mammalian cells that express antibody in a cell culture production medium; wherein the cell culture process includes use of basal medium, use of concentrated basal medium as feed solution, use of feed solutions along-with a definite feeding strategy, results in enhanced cell growth, maintaining lower concentrations of lactate and ammonia, effectively maintaining the cell count thereby increasing cell longevity and high yield.
- 3. The method of claim 2, wherein the cell culture medium comprises of atleast one medium selected from the group comprising of Cell Vento 220 (Merck), ACTIPRO (HyClone/GE), Gibco™ Dynamis™ Medium (Thermo Fisher).
- 4. The method of claim 1-3, wherein the cell culture medium is supplemented with one or more other nutrients, atleast once during the process.
- 5. The method of claim 1 and 4, wherein the cell culture production medium is supplemented on a schedule comprising supplémentation that is continuous, daily, every other day, every two days and combination thereof.
- 6. The method of claim 4, wherein the cell culture production medium is supplemented with feed solution comprising of atleast one medium selected from the group comprising of Glucose, Cell Boost™ 5 Supplément (Hyclone), EX-CELL 293 (Sigma Aldrich), Cell Boost 7a and 7b suppléments (Hyclone), 3X Actipro medium, Cell Vento 220 (3X medium), EX-CELL® Advanced™ CHO Feed 1, EfficientFeed™ A, EfficientFeed™ B, and EfficientFeed™ C, and combination thereof.
- 7. The method of claim 1 ; wherein the cell count is in the range of 10 x 106 - 20 x 106 cells/ml.
- 8. The method of claim 1, wherein the cell culture medium has Osmolality in range of 250 500mOsm/Kg; pH in range of 6.5 - 7.5; dissolved oxygen is maintained in range of 10 - 60%; Cell culture température is in the range of 30°C to 38°C; first température preferably 36 - 37 °C and optionally second température preferably 30 - 35 °C; Glucose concentration is maintained below 7%; preferably between 4% and 5% ; harvesting the cell culture when viability is decreased to 80 %; wherein the cell culture conditions are maintained in a manner that secondary métabolites such as Lactate concentration is not more than 5g/L; and Ammonia concentration is not more than 5 mMol/L
- 9. The method of claim 8, wherein the Osmolality of the fermentation medium is 400 - 500 mOsm/kg.
- 10. The method of claim 1, wherein the dissolved oxygen of the fermentation medium is maintained in the range of 20 - 40%.
- 11. The method of claim 1, wherein antigen binding protein is selected from the group comprising of humanized antibody, chimeric antibody, human antibody, bispecific antibody, multivalent antibody, multi-specific antibody,antigen binding protein fragments, polyclonal, monoclonal, diabodies, nanobodies, monovalent, bispecific, heteroconjugate, multispecific, autoantibodies, single chain antibodies, Fab fragments, F(ab)'2, fragments, fragments produced by a Fab expression library, antiidiotypic (anti-ld) antibodies, epitope-binding fragments and CDR-containing fragments and combination thereof.
- 12. The method of claim 1, wherein the cell line is selected from the group consisting of Chinese Hamster Ovary (CHO) cells, GS - CHO, CHOK1SV GS-KO, CHO DUX-B11, CHO-K1, BSC-1, NS0 myeloma cells, CV-1 in Origin carrying SV40 (COS) cells, COS-1, COS-7, P3X3Ag8.653, SP2 cells, human embryonic kidney (HEK 293) cells, baby hamster kidney (BHK 21) cells, African green monkey kidney VERO-76 cells, HELA cells, human lung cells (W138), Retinal cells, and human hepatoma line (Hep G2). VERO, BHK, MDCK, WI38 cells, NIH-3T3, W138, BT483, Hs578T, HTB2, BT20, T47D, NS0 (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, HsS78Bst cells, PER.C6, SP2/0-Ag14, a myeloma cell line, a hybridoma cell line, human lung cells (W138), Retinal cells, human hepatoma line (Hep G2), CHO— K1 (ATCC CCL-61), DG44 (Chasin étal., 1986, Som. Cell Molec. Genet, 12:555-556; and Kolkekar et al., 1997, Biochem., 36:10901-10909), SH87 cellCHO-DXB11 (G. Urlaub and L. A. Chasin, 1980 Proc. Natl. Acad. Sci., 77: 4216-4220. L. H. Graf, and L. A. Chasin 1982, Molec. Cell. Biol., 2: 9396), CHO—K1 Tet-On cell line (Clontech), CHO designated ECACC 85050302 (CAMR, Salisbury, Wiltshire, UK), CHO clone 13 (GEIMG, Genova, IT), CHO clone B (GEIMG, Genova, IT), CHO— K1/SF designated ECACC 93061607 (CAMR, Salisbury, Wiltshire, UK), RR—CHOK1 designated ECACC 92052129 (CAMR, Salisbury, Wiltshire, UK), CHOKIsv (Edmonds et al., Mol. Biotech. 34:179-190 (2006)), CHO—S (Pichler et al., Biotechnol. Bioeng. 108:386-94 (2011)), dihydrofolate reductase négative CHO cells (CHO/-DHFR, Urlaub and Chasin, 1980, Proc. Natl. Acad. Sci. USA, 77:4216), and dp12.CHO cells (U.S. Pat. No. 5,721,121); monkey kidney CV1 cells transformed by SV40 (COS cells, COS-7, ATCC CRL-1651); human embryonic kidney cells (e.g., 293 cells, or 293 cells subcloned for growth in suspension culture, Graham et al., 1977, J. Gen. Virol., 36:59); baby hamster kidney cells (BHK, ATCC CCL-10); CAP cell, AGE1.HN cell, monkey kidney cells (CV 1, ATCC CCL-70); African green monkey kidney cells (VERO-76, ATCC CRL-1587; VERO, ATCC CCL-81); mouse sertoli cells (TM4, Mather, 1980, Biol. Reprod., 23:243-251); human cervical carcinoma cells (HELA, ATCC CCL-2); canine kidney cells (MDCK, ATCC CCL-34); human lung cells (W138, ATCC CCL-75); human hepatoma cells (HEP-G2, HB 8065); mouse mammary tumor cells (MMT 060562, ATCC CCL-51); buffalo rat liver cells (BRL 3A, ATCC CRL-1442); TR1 cells (Mather, 1982, Ann. NY Acad. Sci., 383:44-68); MCR 5 cells; and FS4 cells and hybridoma cells
- 13. The method of claim 1, wherein the cell line is CHO-K1 SV GS-KO.
- 14. The method of claim 1, wherein the cell line is GS - CHO.
- 15. The method of claim 1, the cells are cultivated in a batch, fed batch , continuons mode, perfusion mode; more particularly in a fed batch mode.
- 16. The method of claim 1, wherein the sait concentration of the buffers used in purification is in the range of 30 mM - 500 mM.
- 17. The method of claim 16, wherein the sait concentration of the buffers used in purification is in the range of 50 mM - 300 mM.
- 18. The method of claim 1, wherein the purification steps comprise of Protein A affinity chromatography, cation exchange chromatography and anion exchange chromatography.
- 19. The method of claim 1, wherein the purification steps comprises of affinity chromatography, Low pH viral inactivation, cation exchange chromatography, anion exchange chromatography, nanofiltration, Tangential flow filtration/Ultrafiltration; in a sequential manner.
- 20. The method of claim 1, wherein the purification steps comprises of affinity chromatography, Low pH viral inactivation, anion exchange chromatography, cation exchange chromatography, nanofiltration, Tangential flow filtration/Ultrafiltration; in a sequential manner.
- 21. The method of claim 1, wherein the affinity chromatography matrix is selected from Protein A, Protein G and Protein L, preferably Protein A.
- 22. The method of claim 1, further comprising additional chromatography step selected from the group comprising one or more of Hydrophobie interaction chromatography, Hydrophobie charge induction chromatography, Ceramic hydroxyapatite chromatography, Multimodal chromatography (Capto MMC and Capto Adhéré), Membrane chromatography (Q membranes including Intercept™ (Millipore), Mustang® (Pall Corporation) and Sartobind™ (Sartorius)).
- 23. The method of claim 21, wherein the protein A chromatography comprises of one or more resins selected from the group comprising of Eshmuno A, KanCapA™, MabSelect SuRe™, MabSelect SuRe LX, MabSelect Xtra, rProtein A Sepharose Fast Flow, Poros® MabCapture A, Amsphere™ Protein A JWT203, ProSep HC, ProSep Ultra, and ProSep Ultra Plus; Preferrably the Protein A affinity chromatography resin is MabSelect SuRe™. Eshmuno A, Kancap A or Poros MabCapture.
- 24. The method of claim 21, wherein the protein A chromatography comprises ofa) Equilibration buffer: 20 mM Phosphate Buffer; 100 - 150 mM NaCI; 0.05% Polysorbate 80; pH 7.0 ± 0.2.b) Loading : Clarified Harvestc) Wash I Buffer: 20 mM Phosphate buffer; 100 - 150 mM NaCI, more particularly 150mM; 0.05% Polysorbate 80; pH 7.0 ± 0.2.d) Wash II Buffer: 20 mM Phosphate buffer; 250 mM - 1 M NaCI, more particularly 1M; 0.05% Polysorbate 80; pH 7.0 ± 0.2.e) Wash III Buffer: 10 mM Phosphate buffer; 100 - 150 mM NaCI, more particularly 125mM; 0.05% Polysorbate 80; pH 7.0 ± 0.2.f) Elution Buffer: 20mM Citrate buffer; pH 3.0 ± 0.2; and optionally 0.025 % (w/v) Polysorbate 80.g) CIP Buffer: 0.1 M NaOH.h) Résidence time: 4.00 - 8.00 minutesi) Column used: XK26j) Linear flow rate is 10 - 500 cm/hr, more particularly 100-150 cm/hr.
- 25. The method of claim 19 and 20, wherein viral inactivation of the eluate from protein A chromatography is accomplished by holding the eluate at pH 3.3 - 3.5 for a period of 50-100 minutes.
- 26. The method of claim 19 and 20, wherein the cation exchange chromatography comprises of resin selected from the group comprising one or more of sulfonate based group (e.g., MonoS, MiniS, Source 15S and 30S, SP SEPHAROSE® Fast Flow, SP SEPHAROSE® High Performance from GE Healthcare, TOYOPEARL® SP-650S and SP-650M from Tosoh, MACRO-PREP® High S from BioRad, Ceramic HyperD S, TRISACRYL® M and LS SP and Spherodex LS SP from Pall Technologies); a sulfoethyl based group (e.g., FRACTOGEL® SE, from EMD, POROS® S-10 and S-20 from Applied Biosystems); a sulphopropyl based group (e.g., TSK Gel SP 5PW and SP-5PWHR from Tosoh, POROS® HS-20, HS 50, and POROS® XS from Life Technologies); a sulfoisobutyl based group (e.g., FRACTOGEL® EMD S03 from EMD); a sulfoxy ethyl based group (e.g., SE52, SE53 and Express-Ion S from Whatman), a carboxymethyl based group (e.g., CM SEPHAROSE® Fast Flow from GE Healthcare, Hydrocell CM from Biochrom Labs Inc., MACRO-PREP® CM from BioRad, Ceramic HyperD CM, TRISACRYL® M CM, TRISACRYL® LS CM, from Pall Technologies, Matrex CELLUFINE® C500 and C200 from Millipore, CM52, CM32, CM23 and Express-Ion C from Whatman, TOYOPEARL® CM-650S, CM-650M and CM-650C from Tosoh); sulfonic and carboxylic acid based groups (e.g., BAKERBOND® Carboxy-Sulfon from J.T. Baker); a carboxylic acid based group (e.g., WP CBX from J.T Baker, DOWEX® MAC-3 from Dow Liquid Séparations, AMBERLITE® Weak Cation Exchangers, DOWEX® Weak Cation Exchanger, and DIAION® Weak Cation Exchangers from Sigma- Aldrich and FRACTOGEL® EMD COO- from EMD); a sulfonic acid based group (e.g., Hydrocell SP from Biochrom Labs Inc., DOWEX® Fine Mesh Strong Acid Cation Resin from Dow Liquid Séparations, UNOsphere S, WP Sulfonic from J.T. Baker, SARTOBIND® S membrane from Sartorius, AMBERLITE® Strong Cation Exchangers, DOWEX® Strong Cation and DIAION® Strong Cation Exchanger from Sigma-Aldrich); and a orthophosphate based group (e.g., PI 1 from Whatman). Preferred Cation-exchange chromatography resin for this invention is Fractogel® EMD SO3“, Fractogel® EMD SE Hicap (Merck), CMM HyperCel™ (Pall Corporation), Capto S ImpAct(GE).
- 27. The method of claim 19 and 20, wherein the cation exchange chromatography comprises ofa) Pre-equilibration buffer: 200 mM Citrate buffer; pH 6.0 ± 0.2b) Equilibration buffer: 10 mM Citrate buffer; 0.025 % (w/v) Polysorbate 80; pH 6.0 + 0.2c) Wash Buffer A: 10 mM Citrate buffer; pH 6.0 ± 0.2d) Wash buffer B: 20 mM Citrate buffer; 300 - 500 mM NaCI; pH 6.0 ± 0.2e) CIP buffer: 0.5M NaOHf) Résidence time: 4.00 - 7.00 minutesg) Column used: XK26
- 28. The method of claim 19 and 20, the anion exchange chromatography comprises of resin is selected from the group comprising one or more of DEAE cellulose, POROS® PI 20, PI 50, HQ 10, HQ 20,HQ 50, D 50 from Applied Biosystems, SARTOBIND® Q from Sartorius, MonoQ, MiniQ, Source 15Q and 30Q, Q, DEAE and ΑΝΧ SEPHAROSE® Fast Flow, Q SEPHAROSE(GE), Q SEPHAROSE® High Performance, QAE SEPHADEX® and FAST Q SEPHAROSE® (GE Healthcare),WP PEI, WP DEAM, WP QUAT from J.T. Baker, Hydrocell DEAE and Hydrocell QA from Biochrom Labs Inc., U Osphere Q, MACRO-PREP® DEAE and MACRO-PREP® High Q from Biorad, Ceramic HyperD Q, ceramic HyperD DEAE, TRISACRYL® M and LS DEAE, Spherodex LS DEAE, QMA SPHEROSIL® LS, QMA SPHEROSIL® M and MUSTANG® Q from Pall Technologies, DOWEX® Fine Mesh Strong Base Type I and Type II Anion Resins and DOWEX® MONOSPHER E 77, weak base anion from Dow Liquid Séparations, INTERCEPT® Q membrane, Matrex CELLUFINE® A200, A500, Q500, and Q800, from Millipore, FRACTOGEL® EMD TMAE, FRACTOGEL® EMD DEAE and FRACTOGEL® EMD DMAE from EMD, AMBERLITE® weak strong anion exchangers type l and II, DOWEX® weak and strong anion exchangers type I and II, DIAION® weak and strong anion exchangers type I and II, DUOLITE® from Sigma-Aldrich, TSK gel Q and DEAE 5PW and 5PW-HR, TOYOPEARL® SuperQ-650S, 650M and 650C, QAE-550C and 650S, DEAE-650M and 650C from Tosoh, QA52, DE23, DE32, DE51, DE52, DE53, Express-Ion D and Express- Ion Q from Whatman; more preferably Anion-exchange chromatography resin is Sartobind Q (Sartorius).
- 29. The method of claim 19 and 20, wherein the anion exchange chromatography comprises ofa) Cleaning buffer: 0.5M NaOHb) Pre-equilibration buffer: 200 mM Citrate buffer; pH 6.0 ± 0.2c) Equilibration buffer: 20 mM Citrate buffer; pH 6.0 ± 0.2; and optionally 0.025% Polysorbate 80d) Storage buffer: 0.1M NaOHe) Linear Flow rate is 10 - 500 cm/hr, more particularly 100-150 cm/hrf) Column used: XK26
- 30. The method of claim 19 and 20, the anion exchange chromatography is “flow through and wash mode” or “bind and elute mode”.
- 31. The method of claim 19 and 20, wherein the removal of viral particles is accomplished by nanofiltration using virus retentive filter selected from the group comprising one or more of Viresolve PRO (Merck), Planova 20N (Asahi Kasei), Bio EXL PALL PEGASUS PRIME, PEGASUS SV4 (Pall Life Sciences), and Virosart (Sartorius), Virosart CPV filter from Sartorius, Virosolve from Millipore, Ultipor DV20 or DV50 from Pall, Planova 20N and 50N or BioEx from Asahi.
- 32. The method of claim 19 and 20, wherein the antigen binding protein is concentrated using Tangential Flow Filtration (TFF).
- 33. The method of claim 32, wherein the TFF is carried out using 30 kDa membrane, selected from the group comprising one or more of Centramate T sériés PES membrane (Pall Corporation), Hydrosart (Sartorius), and Pelicon 3 (Merck), preferably using Centramate T sériés PES membrane (Pall Corporation).
- 34. The method of claim 32, wherein the Tangential Flow Filtration process comprises ofa) Diafilteration using diafilteration buffer: 25 mM Histidine buffer; 75 mM Arginine buffer; 50 150 mM NaCI; pH 6.50 ± 0.5.b) Cleaning buffer: 0.5M NaOHc) Storage buffer: 0.1 M NaOHd) Equilibration using 5 - 10 X membrane volumee) Concentration and Diafiltration using 10-20 diafiltration volumef) WFI wash using 3 - 5 membrane volumeg) cleaning using 0.5 - 1.0 M NaOHh) Storage 0.1 M NaOH
- 35. The method of claim 1, wherein the purified therapeutic protein préparation contain no greater than 2% aggregates, preferably less than 1% aggregates.
- 36. The method of claim 1, wherein the stable antigen binding protein formulation comprises of atleast one antigen binding protein, atleast one Stabilizer, atleast one Buffer, atleast one Tonicity agent , and atleast one surfactant.
- 37. The method of claim 36, wherein stabilizer is a carbohydrate selected from the group comprising one or more of sucrose, sorbitol, trehalose, mannitol, dextran, inositol, glucose, fructose, lactose, xylose, mannose, maltose, or Raffinose; more preferably stabilizer is sucrose.
- 38. The method of claim 37, wherein the stable antigen binding protein formulation comprises of <2.5% sucrose, more preferably <1% sucrose, and most preferably 0.5% sucrose.
- 39. The method of claim 36, wherein the buffering agent is selected from group comprising of one or more of Histidine, Glycine, Sodium Citrate, Sodium Phosphate, Arginine, Citric Acid, HEPES, Potassium Acetate, Potassium Citrate, Potassium Phosphate, Sodium Acetate, Sodium Bicarbonate, Tris Base, and Tris-HCI.
- 40. The method of claim 39, wherein the buffering agent is Histidine or Arginine or combination thereof.
- 41. The method of claim 36 and 39, wherein the buffering agent is Histidine.
- 42. The method of claim 41, wherein the concentration of Histidine is in the range of 10 - 50 mM; preferably 25 mM.
- 43. The method of claim 36 and 39, wherein the buffering agent is Arginine.
- 44. The method of claim 43, wherein the concentration of Arginine is in the range of 10 - 150 mM; preferably 75 mM.
- 45. The method of claim 36, wherein the tonicity agent is selected from the group comprising one or more of sodium chloride, dextrose, glycerin, mannitol, and potassium chloride.
- 46. The method of claim 45, wherein the tonicity agent is sodium chloride.
- 47. The method of claim 45, wherein the concentration of sodium chloride is in the range of 50 - 250 mM; preferably 100-145 mM.
- 48. The method of claim 36, wherein the surfactant is selected from the group comprising of one or more of polysorbates (e.g. polysorbate-20 or polysorbate-80); poloxamers (e.g. poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium laurel sulfate; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g. lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl oleyl-taurate; and the MONAQUAT® sériés (Mena Industries, Inc., Paterson, N.J.), polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g. Pluronics, PF68 etc);preferably the surfactant is polysorbate 80.
- 49. The method of claim 48, wherein the concentration of Polysorbate 80 is in the range of 0.002 - 0.2% (w/v) ; preferably 0.02%( w/v).
- 50. The method of claim 1 and 36 - 48, wherein the stable antigen binding protein formulation comprises of about 1 mg/ml to about 100 mg/ml of antigen binding protein.
- 51. The method of claim 50, wherein the stable antigen binding protein formulation comprises of about 1 mg/ml to about 50 mg/ml of antigen binding protein.
- 52. The method according to any of the preceding daims, wherein antigen binding protein formulation comprises of not more than 3% aggregation, minimum amount of sub-visible particles and improved potency.
- 53. The method of claim 1, wherein the concentration of the antigen binding protein monomer is greater than 99%; residual CHO DNA is not more than 2 pg/mg of antigen binding protein, more particularly not more than 0.1 pg/mg of antigen binding protein; residual CHO protein is not more than 100 ng/mg of antigen binding protein, more particularly not more than 10 ng/mg of antigen binding protein; residual Protein-A is not more than 10 ng/mg of antigen binding protein, more particularly not more than 1.5 ng/mg of antigen binding protein; Endotoxin is not more than 0.1 EU/mg of protein,viral clearance LRV for MuLV is atleast 15 Iog10,réduction factor and for MMV is atleast 12 Iog10,réduction factor.
- 54. A pharmaceutical composition prepared according to any of the preceding daims.
- 55. A pharmaceutical formulation comprising of antigen binding protein, a buffering agent, a tonicity agent, a surfactant and a stabilizing agent.
- 56. A pharmaceutical formulation of daim 55, wherein stabilizer is a carbohydrate selected from the group comprising one or more of sucrose, sorbitol, trehalose, mannitol, dextran, inositol, glucose, fructose, lactose, xylose, mannose, maltose, or Raffinose; more preferably stabilizer is sucrose.
- 57. A pharmaceutical formulation of claim 56, wherein the stable antigen binding protein formulation comprises of <2.5% sucrose w/v, more preferably <1% sucrose w/v.
- 58. A pharmaceutical formulation of claim 55, wherein the buffering agent is selected from group comprising of one or more of Histidine, Glycine, Sodium Citrate, Sodium Phosphate, Arginine, Citric Acid, HEPES, Potassium Acetate, Potassium Citrate, Potassium Phosphate, Sodium Acetate, Sodium Bicarbonate, Tris Base, and Tris-HCI.
- 59. A pharmaceutical formulation of daim 58, wherein the buffering agent is Histidine or Arginine or combination thereof.
- 60. A pharmaceutical formulation of claim 55, wherein the buffering agent is Histidine.
- 61. A pharmaceutical formulation of daim 60, wherein the concentration of Histidine is in the range of 10- 50 mM; preferably 25 mM.
- 62. A pharmaceutical formulation of daim 55, wherein the buffering agent is Arginine.
- 63. A pharmaceutical formulation of claim 62, wherein the concentration of Arginine is in the range of 10- 150 mM; preferably 75 mM.
- 64. A pharmaceutical formulation of claim 55, wherein the tonicity agent is selected from the group comprising one or more of sodium chloride, dextrose, glycerin, mannitol, and potassium chloride.
- 65. A pharmaceutical formulation of claim 64, wherein the tonicity agent is sodium chloride.
- 66. A pharmaceutical formulation of claim 65, wherein the concentration of sodium chloride is in the range of 50 - 250 mM; preferably 100 - 145 mM.
- 67. A pharmaceutical formulation of claim 55, wherein the surfactant is selected from the group comprising of one or more of polysorbates (e.g. polysorbate-20 or polysorbate-80); poloxamers (e.g. poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium laurel sulfate; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g. lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl oleyl-taurate; and the MONAQUAT® sériés (Mona Industries, Inc., Paterson, N.J.), polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g. Pluronics, PF68 etc); preferably the surfactant is polysorbate 80.
- 68. A pharmaceutical formulation of claim 67, wherein the concentration of Polysorbate 80 is in the range of 0.002 - 0.2% (w/v) ; preferably 0.02% (w/v).
- 69. A pharmaceutical formulation comprising ofa) 1-100 mg/ml of atleast one antigen binding protein;b) 20 - 40 mM of Histidine;c) 50 - 100 mM of Arginine;d) 0.002 - 0.02% Polysorbate 80 (w/v);e) 50- 150 mM NaCI;f) not more than 2.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5.wherein the Osmolality of the formulation is 300 - 450 mOsmol/kg and viscosity less than 2.5 mPa-S and said formulation is stable at 2-8 deg C for atleast 9 months, at 25 deg C for atleast 1 month , at 40 deg C for atleast 40 days, at 50 deg C for atleast 2 days
- 70. A pharmaceutical formulation comprising of 2 - 80 mg/ml of atleast one antigen binding protein; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5.
- 71. A pharmaceutical formulation according to any of the preceding claims, wherein isoelectric point (pl) of said antigen binding protein is 7.0- 8.5.
- 72. A pharmaceutical formulation according to any of the preceding claims, wherein the Osmolality of the formulation is about 380 mOsmol/kg.
- 73. A pharmaceutical formulation according to any of the preceding claims, wherein said antigen binding protein is an humanized antibody, chimeric antibody, human antibody, bi-specific antibody, multivalent antibody, multi-specific antibody, antigen binding protein fragments, polyclonal antibody, monoclonal antibody, diabodies, nanobodies, monovalent, hetero-conjugate, multi-specific, autoantibodies, single chain antibodies, Fab fragments, F(ab)'2, fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-ld) antibodies, epitope-binding fragments and CDR-containing fragments or combination thereof.
- 74. A pharmaceutical formulation according to claim 73, wherein said antigen binding protein is a monoclonal antibody.
- 75. A pharmaceutical formulation according to claim 73, wherein said monoclonal binds to a dengue virus.
- 76. A pharmaceutical formulation according to claim 73, wherein said monoclonal antibody binds to a rabies virus.
- 77. A pharmaceutical formulation comprising of 2 - 80 mg/ml of Dengue monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
- 78. A pharmaceutical formulation comprising of 25 mg/ml of Dengue monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
- 79. A pharmaceutical formulation comprising of 50 mg/ml of Dengue monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 + 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
- 80. A pharmaceutical formulation comprising of 2 - 80 mg/ml of Rabies monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
- 81. A pharmaceutical formulation comprising of 25 mg/ml of Rabies monoclonal antibody; 25 mM of Histidine; 75 mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
- 82. A pharmaceutical formulation comprising of 50 mg/ml of Rabies monoclonal antibody; 25 mM of Histidine; 75mM of Arginine; 101 mM NaCI; 0.02% Polysorbate 80 (w/v); and 0.5% Sucrose w/v; wherein pH of the formulation is 6.5 ± 0.5 Osmolality 380 mOsm/Kg, viscosity less than 2.5 mPa-S.
- 83. A pharmaceutical formulation according to any of the preceding daims, wherein the formulation is a liquid formulation.
- 84. A pharmaceutical formulation according to any of the preceding daims, wherein the formulation is a lyophillized formulation.
- 85. A pharmaceutical composition as claimed in claim 70, wherein the antigen binding protein is an antibody having binding affinity towards epitopes présent on Dengue virus, Rabies virus, RSV, MPV, Influenza virus, Zika virs, West Nile virus,Yellow fever virus, chikungunya virus, HSV, CMV, MERS, Epstein-Barr virus, Varicella-Zoaster virus, mumps virus, measles virus, polio virus, rhino virus, adenovirus, hepatitis A virus, Hepatitis B virus, hepatitis C virus, Norwalk virus, Togavirus, alpha virus, rubella virus, HIV virus, Marburg virus, Ebola virus, Human pappiloma virus, polyoma virus, metapneumovirus, coronavirus,Ebola virus, VSV and VEE.
- 86. A pharmaceutical composition as claimed in claim 70, wherein the antigen binding protein is selected from the group comprising of one or more of CTP19 , CR57 , CR4098, RVFab8, MabJA, MabJB-1, Mab 57,1707, 2B10, Ab513/VIS513, N297Q-B3B9 , Mab2E8 , 2D22, DMScHuMab,3CH5L1, HMB DV5, HMB DV6, HMB DV8, DB32-6, D88, F38, A48, C88, F108, B48, A68, A100, C58, C78, C68, D98, D188, C128, C98, A11, B11, R17D6, R14B3, R16C9, R14D6, R18G9, R16F7, R17G9, R16E5 , antibodies derived from modification of 4E11 A.adataœpt, abciximab, adalimumab, aflibercept, alefacept, alemtuzumab.trastuzumab, basiliximab, bevacizumab, belatacept, bectumomab, certolizumab, cetuximab, daclizumab, eculizumab, efalizumab, entanercept, gemtuzumab, ibritumomab, infliximab, muromonab-CD3, omalizumab, palivizumab; panitumumab, pertuzumab, ranibizumab, rilonacept, rituximab, tositumomab, trastuzumab, zanolimab, nivolumab, pembrolizumab ,hA20, AME-I33, IMC-3G3, zalutumumab, nimmotuzumab, matuzumab, ch*)A, KSB102, MR1-1, SC100, SC101, SC103, muromonab-CD3, OKT4A, ibritumomab, gemtuzumab, motavizumab, infliximab, pegfilgrastin, CDP-571, etanercept, ABX-CBL , ABX-IL8, ABX-MAI pemtumomab, Therex, AS1405, natalizumab, HuBC-l, IDEC-131, VLA-I; CAT- 152; J695, CAT- 192, CAT-213, BR3-Fc, LymphoStat-B, TRAIL-RImAb , bevacizumab, omalizumab, efalizumab, MLN-02, HuMax-IL 15, HuMax-Inflam, HuMax-Cancer, HuMax-Lymphoma, HuMax-TAC, clenoliximab, lumiliximab, BEC2, IMC-ICI 1, DCIOI, labetuzumab, arcitumomab, epratuzumab, tacatuzumab, Cetuximab, MyelomaCide, LkoCide, ProstaCide, ipilimumab, MDX-060, MDX-070, MDX-018, MDX1106, MDX-1103, MDX-1333, MDX-214, MDX-1100, MDX-CD4, MDX- 1388, MDX-066, MDX-1307, HGS-TR2J, FG-3019, BMS-66513, SGN-30, SGN-40, tocilizumab, CS-1008, IDM-I, golimumab, CNTO 1275, CNTO 95, CNTO 328, mepolizumab, MORIOI, MORI 02, MOR201, visilizumab, HuZAF, volocixmab, ING-l, MLN2201, daclizumab, HCD 122, CDP860, PRO542, C 14, oregovomab, edrecolomab, etaracizumab, atezolizumab ,iplimumab,mogamulizumab, lintuzumab, HulDIO, Lym-1, efalizumab, ICM3, galiximab, eculizumab, obinutuzumab.pexelizumab, LDP-OI, huA33, WX-G250, sibrotuzumab, ofatumumab, Chimeric KW-2871, hu3S193, huLK26; bivatuzumab.raxibacumab, chl4.18, 3F8, BC8, huHMFGI, MCRAb-003, MORAb-004, MORAb-009, denosumab, PRO-140, 1D09C3, huMikbeta-1, NI-0401, NI-501, cantuzumab, HuN901, 8H9, chTNT1/B, bavituximab, huJ591, HeFi-l, Pentacea, abagovomab, tositumomab, ustekinumab,105AD7, GMAI 61, GMA321.
- 87. A pharmaceutical formulation according to any of the preceding daims, wherein said antigen binding protein is an anti-dengue antibody or anti-rabies antibody that can be administered alone or in combination with other agents , other prophylactic or therapeutic modalities.
- 88. A container comprising the formulation of any of the preceding daims, wherein the container is selected from a bottle, a vial, a glass vial, an ampule, an IV bag, a form/blow-fill seal container, a wearable injector, a bolus injector, a syringe, a pen, a pump, a multidose needle syringe, a multidose pen, a injector, a syrette, an autoinjector, a pre-filled syringe, or a combination thereof.
- 89. A container comprising the formulation of claim 88, wherein at least one primary packaging component comprises a container closure selected from glass, polypropylene (PP), polyethylene terephthalate (PETG), high-density polyethylene (HDPE), polyethylene terephthalate (PET), polypentafluorostyrene (PFS), poly carbonate, polyvinyl chloride (PVC), polycyclopentane (CZ.RTM.), cyclic olefin copolymer (COC), polyolefin, and combinations or copolymers thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621044139 | 2016-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19248A true OA19248A (en) | 2020-04-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7265477B2 (en) | Improved methods, formulation methods and resulting stable antibody formulations for increasing antibody productivity and minimizing aggregation in downstream mammalian cell cultures | |
US9522953B2 (en) | Low acidic species compositions and methods for producing and using the same | |
AU2013384204B2 (en) | Low acidic species compositions and methods for producing and using the same | |
US9499614B2 (en) | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides | |
US20170306009A1 (en) | Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen | |
US20170121403A1 (en) | Modulated lysine variant species compositions and methods for producing and using the same | |
EP3344278A2 (en) | Insulin immunoglobulin fusion proteins | |
OA19248A (en) | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof. |